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ABSTRACT 
 Label free detection of biologically relevant binding pairs has provided critical in-
sight into the characterization of reagents used in both therapeutic and diagnostic applica-
tions.  The Interferometric Reflectance Imaging Sensor (IRIS) platform has been developed 
for the multiplexed, real-time detection of such binding interactions.  Improvements to ex-
perimental methodology and analysis applied to the latest iteration of the IRIS provided 
heretofore unseen binding characterizations with this multiplexed platform.  Here, we ex-
tend and demonstrate the utility of the IRIS system to (1) evaluate and compare kinetic 
parameters to those obtained with more traditional label free methods  (2) characterize 
multiple, disease relevant antibodies in multiple disease systems (anthrax, Zika, dengue 
and plague) (3) determine appropriate binding pairs in multiplexed label free formats and 
(4) obtain 10-fold improvements to the limits of detection for analyte in solution over pre-
vious IRIS iterations.  Applications to immunoassay development are discussed throughout 
with exemplary datasets provided.  Observations regarding additional IRIS utilities are also 
discussed, including qualifications of genetically engineered ligands, evaluating subcloned 
antibodies and screening unpurified antibody supernatants.  
 vii 
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Chapter 1 Introduction 
The need to understand the rates of reaction for serologically specific interactions has been 
of significant import to diagnostic and clinical applications for several decades.  The speed 
of antibody-antigen binding kinetics was first estimated using ‘rules of thumb’ 
(Landsteiner, 1962) and ultimately matured to more sophisticated surface plasmon 
resonance (SPR) and biolayer interferometry (BLI) techniques that provided second-by-
second interaction kinetics.  In every case, the understanding, selection, and modification 
of potential binding partners drives a significant portion of the decisions made in diagnostic 
assay design and antibody-based therapeutics (Dysinger & King, 2012) (Singh P. , 2016) 
(Homola, 2008) (Markwalter, Jang, Burton, Domingo, & Wright, 2017). 
 
Specific antibody-antigen interactions have long been of interest since the fundamental 
understanding of immunology developed over the course of the 20th century with 
significant contributions by such great thinkers as Paul Ehrlich and Karl Landsteiner 
(Silverstein, 2009). Methods for analysis have developed over time and have included 
agglutination, complement fixation, western blots, enzyme immunoassays (e.g., ELISA), 
and fluorescent immunoassays, among others.  However, these methods typically rely upon 
the indirect detection of the actual analyte of interest; that is, an antibody or ligand must 
typically be bound to a reporter (enzyme, particle, fluorophore, etc.) of some kind and this 
reporter provides the signal that is measured.  While clinically useful, expedient, and 
historically robust, these methods are inherently limited when it comes to screening real-
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time binding events and require the need for reagent labeling and corresponding secondary 
antibodies.   
 
A ‘label-free’, sensitive and robust screening platform is, therefore, of some significant 
utility.   Benefits of such a technique include the determination of rate constants (𝑘𝑜𝑛 and 
𝑘𝑜𝑓𝑓) without the need for fluorophores, enzymes, nanoparticles or even secondary 
antibodies.  Well established methodologies now include surface plasmon resonance (e.g., 
Biacore) and biolayer interferometry (e.g., ForteBio) and each method has some degree of 
utility and drawbacks and the chosen tool should reflect the specific needs of the researcher 
(Yang, Singh, Wu, & Kroe-Barrett, 2016). 
 
Surface plasmon resonance is particularly suited to evaluate one ligand-analyte pair at a 
time and relatively complex and expensive methods have been only recently been 
developed to attempt to create arrays for SPR imaging (SPRi); a format which presents 
unique challenges and limitations (Singh P. , 2016) (Yang, Singh, Wu, & Kroe-Barrett, 
2016).  The significant impact of the refractive index on the SPR signal must also be taken 
into account and careful control flow cells must typically be run for every experiment.  The 
apparent noise floor of SPR may be detrimentally impacted when using the SPRi modality 
(Yang, Singh, Wu, & Kroe-Barrett, 2016).  
 
Biolayer interferometry uses a physical principle based upon the interference pattern of 
electromagnetic waves that shift when binding occurs at the interface.  This analytical tool 
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has grown in popularity, in part, due to the ease of evaluating multiple analytes by 
functionalizing multiple tips with an antibody of interest.  However, there are some 
limitations for the application of BLI while evaluating multiple ligands with occasionally 
precious analyte.  For instance, ligands typically need to be conjugated to biotin in order to 
be specifically associated to a streptavidin labeled probe or attached (adsorbed or 
chemically linked) to an aminosilane surface (Zhao, et al., 2016) or linked via an antibody 
intermediary (Yang, Singh, Wu, & Kroe-Barrett, 2016).  It is required to observe the 
binding of the ligand to the sensor surface to assure and record the efficiency of the ligand 
attachment step.  Such attachment techniques may be time consuming and/or have 
deleterious impacts on the functionality of the ligand itself or cause complications in the 
analysis of binding kinetics.  Additionally, the limited mixing, sample evaporation and 
physically switching tips from one buffer to another may cause significant complications 
for data interpretation.  Limits to the experimental procedure (i.e., length of time) may be 
present due to sample evaporation in ELISA plate wells.  Mass transport limitations are – 
out of necessity – reduced by the rapid shaking of the ELISA plate platform.  Each tip must 
be removed from one buffer and subsequently placed into another nearby well that holds 
the next buffer in the experiment; this causes artificial ‘jumps’ in data acquisition which 
must be aligned via software analysis.   
  
Additional techniques include isothermal titration calorimetry and differential scanning 
fluorimetry; each has its own benefits and limitations.  Isothermal titration calorimetry may 
require competition experiments with a weaker inhibitor when working with high affinity 
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molecules and is limited in throughput.  Differential scanning fluorimetry provides 
methodology for screening potentially hundreds of ligands simultaneously for 
approximations of 𝐾𝐷, but direct measurements of 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 may not be so readily 
obtained (Leavitt & Freire, 2001) (Vivoli, Novak, Littlechild, & Harmer, 2014).    
 
Given the above, the Interferometric Reflectance Imaging Sensor (IRIS) has been 
developed to fit an existing need for simple, inexpensive and sensitive multiplexed (array-
based) detection of real time binding events.  This imaging-based technique – by primary 
design – permits for easy and robust ligand multiplexing while using limited sample 
volume (e.g., ~600 µl of diluted analyte).  The IRIS system incorporates a functionalized 
Si/SiO2 chip that may be spotted with ligands (protein, DNA, etc.) in an array format.  The 
chip is then enclosed in a small microfluidic chamber by the simple use of a gasket and an 
anti-reflective (AR) coated glass slide.  Buffers and specimens of interest may then be 
injected (flowed) directly over the chip in a similar manner that is used for SPR.  Incident 
light passes through the glass slide, through the buffer and reflects off the interface of the 
silicon/silicon dioxide (Si/SiO2) chip.  As a 4-color light-emitting diode (LED) based 
system for IRIS is utilized, it is possible to switch wavelengths to optimize for direct 
analyte detection and also for the detection of other nanoparticles (e.g., gold nanoparticles).  
Single gold nanoparticle binding events are also discernible using high magnification 
settings (Sevenler, Ünlü, & Ünlü, 2015).  Significantly, data collected via IRIS 
methodology does not exhibit artificial ‘jumps’ while switching between one buffer to the 
next. Unlike SPR and BLI, there is no need to artificially align the binding and de-binding 
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curves further simplifying data analysis.  Additionally, there is no need to separately 
monitor the binding of the ligand to the sensor surface as the direct quantity (e.g., the 
nanometers of thickness) of the spotted ligand are determined directly.  The IRIS system 
may be the only optical label-free detection system which uses a normally incident light 
source that passes through the target (analyte) solution; in doing so, it may provide unique 
data sets and methods for monitoring binding kinetics. 
 
Here, we describe in detail the methods and results obtained when using the array-based 
IRIS system for multiplexed detection of analyte associating to bound ligand(s).  The data 
collection, analysis, and direct comparisons to published results with SPR and BLI are 
presented.  The IRIS system, chip description and surface functionalization are first 
discussed to lay the groundwork of the subsequent sections.  Analysis methods and 
validation of the obtained kinetic parameters are also discussed in detail.  Sections 
describing the extension of the IRIS to multiplexed analyte-ligand binding, applications to 
assay design, “sandwiching” steps in IRIS assays, limits of detection and additional novel 
applications of the IRIS platform are presented with supporting data. 
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Chapter 2 The Interferometric Reflectance Imaging Sensor (IRIS) System 
The IRIS system depends upon a simple optical principle: the interference of normally 
incident electromagnetic waves on a well-defined layered substrate.  An overview of the 
IRIS system is shown in Figure 1.  Normally incident light from the light emitting diode 
(LED) passes through the AR coated glass slide, through the buffer and subsequently re-
flects from both the top and bottom surfaces of the silicon-silicon oxide (Si/SiO2) chip.  
The measured intensity of the interference pattern generated at the far-field with a normally 
incident light source can be estimated by the following (Özkumur, et al., 2008): 
 
𝑅 = |𝑟|2 =
𝑟1
2+𝑟2
2+2𝑟1𝑟2 cos(2𝜑)
1+𝑟1
2𝑟2
2+2𝑟1𝑟2 cos(2𝜑)
   (1) 
 
where 𝜑 =
2𝜋𝑑
𝜆
𝑛𝑆𝑖𝑂2.  The factors 𝑟1 and 𝑟2 are the Fresnel reflection coefficients of the 
buffer/SiO2 interface and the SiO2/Si interface, respectively, 𝑑 is the thickness of the oxide 
surface, 𝜆 is the wavelength of the incident light and 𝑛𝑆𝑖𝑂2 is the wavelength dependent 
refractive index of the oxide layer.  As biomass accumulates at any given spot, the optical 
path is altered which can be detected as a phase shift.  If one approximates the refractive 
index of the adsorbed protein as roughly equivalent to the SiO2 layer (Vörös, 2004) 
(Malitson, 1965), it is possible to estimate the approximate effective thickness (nm) and 
concentration (pg/mm2) of protein at a given spot. 
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Figure 1.  Electromagnetic waves incident on the chip surface (a) undergo a phase shift 
as (b) biomass is accumulated at the surface.  The shift in phase is detected at the camera 
sensor as a variation in intensity (c).  Real time binding events of an array of ligands may 
be recorded during the experiment.  See (Avci, Lortlar Ünlü, Özkumur, & Ünlü, 2015) for 
additional reference. 
 
The IRIS has developed over several iterations, from utilizing a laser light source, a rotating 
ground glass and large flow cell (Özkumur, et al., 2008) to a more simplified and rugged 
multi-LED system, integrating sphere and a correspondingly simplified microfluidic 
chamber (Avci, Ünlü, Özkumur, & Ünlü, 2015).  
 
Early generations of the device required the use of a sophisticated laser light source that 
swept through the optical wavelengths.  Spatial coherence was eliminated by incorporating 
a rotating ground glass along the optical path.  The light was a passed through a 50:50 beam 
splitter such that light would be incident onto the flow cell, hit the chip surface and the 
reflected light was captured with a CCD camera.  Images were collected as a function of 
time and each pixel would then be fit to the governing equations to estimate the thickness 
of the surface. 
 
(b) (c) (a) 
Simplified operating principle of the Interferometric Reflectance Imaging Sensor 
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As the IRIS developed, several improvements were incorporated, as seen in Figure 2.  
Importantly, the use of well characterized LED’s in conjunction with an integrating sphere 
significantly reduced the cost and complexity of the IRIS while eliminating spatial 
coherence and the need for a rotating ground glass.  Additionally, the use of through-silica-
via (TSV) holes in the chip surface permitted the simple creation of a disposable 
microfluidic chamber by incorporating a simple gasket and an anti-reflective coated glass 
slide.  In the following, we will examine each of the critical components of the IRIS system 
such that a fundamental understanding of the optics, chip and microfluidic chamber may 
be readily obtained. 
 
 
Figure 2.  The evolution of the IRIS system (formerly spectral reflectance imaging 
biosensor, SRIB), is depicted here, reproduced from (Avci, Ünlü, Özkumur, & Ünlü, 2015).  
Newer prototypes, using LED illumination sources, have significantly improved the 
robustness and minimized the size of the IRIS.  
Conceptually, the experimental setup is broken down in terms of the optics, the IRIS chip, 
the microfluidic chamber, the stage and the fluidic handling.  The current IRIS system is 
described in some detail in the following sections.   
Developmental stages of IRIS platform 
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Optical set-up: 
The fundamental IRIS components have been thoroughly described in several publications 
(Avci, Ünlü, Özkumur, & Ünlü, 2015) (Reddington, 2014) (Needham, Lortlar Ünlü, 
Yurdakul, & Ünlü, 2019).  The currently used optical system consists of six primary 
components:  the LED’s, the integrating sphere, the 50:50 beam splitter, the objective, an 
elliptical turn-mirror and a CMOS camera.   
 
LEDs:  Spatiotemporally low coherent, four-color LED’s (LED Engin, LZ4-00MA00) are 
attached to an integrating sphere to provide a uniform illumination source.  The four-color 
LED’s consist of: red (dominant wavelength, λD = 630 nm), green (λD = 525 nm), blue (λD 
= 460 nm), and yellow (λD = 595 nm).  
 
Integrating sphere: The integrating sphere (Thorlabs, IS236A-4) allows for multiple inter-
nal reflections of the incoming light in order to provide an approximately uniform illumi-
nation source (low spatial coherence) for the chip surface.  
 
Beam splitter: This is a 50:50 beam splitter sourced through Thorlabs (CCM1-BS013).  
Incident light is re-directed to the IRIS chip surface while also permitting reflected light 
from the IRIS chip to pass to the turn-mirror and camera. 
 
Objective:  A 2X/0.06 NA or 5X/0.1 NA objective (Nikon) is typically used, depending 
upon the field-of-view (FOV) that is desired.   
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Turn-mirror:  An elliptical, silver coated 45º mirror (Thorlabs, PFE10-P01) is mounted in 
order to rotate the collection path by 90º while preventing artificial clipping of the collected 
light. 
 
Camera:  A 5 MP CMOS camera (FLIR, Grasshopper3 GS3-U3-51S5M-C) is used for 
data collection.  The camera sensor size is 8.445mm x 7.065mm with a pixel size of 
3.45µm.  The FOV is determined by the camera sensor and the selected objective (2X or 
5X, for example).  Using a 2X objective, an approximate 4.2mm x 3.5mm FOV is obtained 
while a 5X objective provides a ~1.7mm x 1.4mm FOV.   
 
A simplified diagram of the optical path for the IRIS system and the corresponding physical 
setup is shown in Figure 3 for reference. 
 
 
Figure 3.  The simplified optical path is shown in (a) while the actual IRIS implementation 
is shown in (b).  The current setup incorporates micromechanical stages to allow for 
precise XYZ positioning of the IRIS chip (Needham, Lortlar Ünlü, Yurdakul, & Ünlü, 2019). 
 
(a) (b) 
Current IRIS platform 
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IRIS chip: 
The chip consists of a 25.2 mm x 12.5 mm section of a diced silicon wafer (Silicon Valley 
Microelectronics) with ~110 nm of thermally grown silicon oxide on top.  Through-silica-
via (TSV) holes are introduced to the chip via laser micromachining (Potomac Photonics).  
Wafers are manufactured by Silicon Valley Microelectronics, Inc. and diced to the 
appropriate size at Boston University.  The Si/SiO2 chip must be functionalized prior to 
spotting proteins or DNA of interest. 
 
The microfluidic chamber: 
By the direct application of a pressure sensitive adhesive (PSA) gasket (Grace Bio-Labs) 
and the addition of a top AR coated glass slide, a natural microfluidic chamber is created 
(see Figure 4).  The chip is placed on a custom fabricated stage as indicated in Figure 6.  
Tubing can connect to both the inlet and outlet ports and an appropriate seal is ensured 
with the use of rubber O-rings in contact with the TSV holes on the chip.   
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Figure 4.  The assembly of the IRIS chip is visualized above.  (a) An AR coated glass slide 
is attached to a double-sided adhesive gasket.  (b) The assembled IRIS chip is shown, 
creating a natural microfluidic chamber.  (c) The scale and physical implementation of a 
sample IRIS chip is shown here (Needham, Lortlar Ünlü, Yurdakul, & Ünlü, 2019). 
 
Care must be taken when aligning the AR glass slide, gasket and IRIS chip in order to 
ensure that the TSV holes are in alignment with the gasket and avoid overhanging material.  
In order to facilitate rapid and robust alignment, a simple 3D printed tool was created to 
permit rapid inverted stacking of the IRIS chip assembly.  Figure 5 shows the CAD model 
and 3D printed prototype used for assembly of the IRIS chip prior to loading onto the stage 
surface. 
 
 
Assembly of IRIS chip, gasket and AR coated slide 
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Figure 5.  A 3D printed alignment tool is used for rapid and precise assembly of the IRIS 
chip prior to loading the chip onto the stage. 
 
The stage: 
The stage consists of a custom fabricated stand with bored holes to accommodate 1/16” 
PTFE tubing.  Additional material is removed from the stand to allow for O-rings to be 
placed at the junction between the tubing and the bottom of the chip surface at the TSV 
holes.  The entire stage is mounted onto a computer controlled XYZ stage to facilitate chip 
placement and focusing.  
 
 
 
 
3D printed prototype for rapid alignment of IRIS chip assembly 
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Figure 6.  A 3D representation of the stage assembly is shown here; the IRIS chip is loaded 
onto the stage and contact is made with O-rings to ensure a completed fluidic path.  A 
spring-loaded cam lever is used to lock a custom cover to the top of the IRIS chip and 
simultaneously apply a small amount of pressure to the TSV hole / O-ring interface 
(Needham, Lortlar Ünlü, Yurdakul, & Ünlü, 2019) (Trueb). 
 
The fluidics: 
All buffers are driven through the fluidic system via a variable speed peristaltic pump 
(Longer Precision Pump, Co, BQ50-1J-A).  A schematic of the fluidic pathway is shown 
in Figure 7.   Fluid speeds typically range from 200 µl/min – 750 µl/min in order to reduce 
mass transport limitations.  Solutions are passed through a de-bubbler (Elveflow) in order 
to reduce the likelihood of unwanted bubbles in the system.  After samples have been 
injected, they may be recirculated in order to preserve sample volume (Abrantes, Magone, 
Boyd, & Schuck, 2001).  Switching between analyte injection and buffer is simply 
performed by altering the specimen loaded into the peristaltic pump.  This can be controlled 
Placement of IRIS chip assembly onto stage platform 
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either manually (while carefully avoiding contamination between buffers) or via a selector 
valve system. 
 
 
 
 
 
 
 
 
 
Figure 7.  A simplified schematic of the key components and fluidic pathway are shown 
here.  Sample selection may be accomplished either manually or via a valve selector.  A 
peristaltic pump drives the solutions through the device.  An inline de-bubbler serves to 
remove unwanted bubbles in the chamber during the assay.  After the solution passes over 
the chip, the line feeds into the waste or may be recycled to conserve more precious 
analytes. 
 
  
Simplified fluidic pathway of IRIS system 
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Chapter 3 Methods 
Surface functionalization 
Prior to spotting the chips with ligands (proteins, DNA, etc.), it is necessary to functionalize 
the oxide surface to provide an available covalent link.  Our group has successfully 
functionalized chip surfaces with epoxysilane (3-(glycidoxipropyl)trimethoxysilane, 
GPTS) and a polymeric coating (MCP-2, Lucidant Polymers) (Seymour, et al., 2015).  
Multiple chips may be functionalized at once and stored under desiccating conditions (e.g., 
under vacuum) to reduce exposure to moisture and encourage complete covalent linkage 
of the silane molecule to the oxide surface.   
 
The experiments described here have used epoxysilane and a brief protocol is included here 
for reference (see additional details in the Appendix).  It is important to use clean, dedicated 
glassware and/or disposable petri dishes to complete the epoxysilanization process.  All 
steps were performed at room temperature.  Chips are first submerged in 1 N NaOH for 1 
hour while rocking gently on a rocker platform.  After exposure to NaOH, the chips are 
subsequently rinsed in a large volume (~1-2 L) of dIH2O to remove any excess salts.  The 
chips are then dried thoroughly using an inert gas (e.g., N2) and placed into a clean petri 
dish.  After the chips have been dried, a fresh 3% (v/v) epoxysilane solution is prepared in 
100% isopropanol.  Chips are incubated in the epoxysilane solution for 1 hour while gently 
swirling or rocking.  Lastly, the chips are rinsed in 100% isopropanol for 5 minutes, dried 
using an inert gas and stored under vacuum before use. 
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The epoxysilane group is shown attached to a reference oxide surface in Figure 8. 
  
 
 
 
 
 
 
 
Figure 8.  The epoxysilane (GPTS: 3-(glycidoxipropyl)trimethoxysilane) functional group 
is shown attached to the silicon oxide surface.  The epoxy group may react with primary 
amines to form a covalent bond with a spotted ligand. 
 
Spotting ligands onto the IRIS chip 
Care must be taken when spotting reagents onto the IRIS chip in order to ensure maximal 
functionality and acceptable spot morphology.  The type of spotter (contact vs. non-con-
tact), spot size and relative hydrophobicity of the surface all must be taken into considera-
tion when spotting the IRIS chip.  Details regarding the spotting conditions used here are 
described in the Appendix, but we briefly describe some of the key parameters here. 
 
While the epoxysilane surface provides a rapid immobilization methodology, its planar 
structure and hydrophobic nature bring additional complexity to the spotting techniques 
employed.  Some effort for proper immobilization and spotting buffer selection was 
necessary in order to obtain consistent spot sizes, morphologies and activities given the use 
Epoxysilane (GPTS) functional group 
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of a benchtop contact spotter (BioRad BioOdyssey Calligrapher™).  While optimal 
spotting buffer conditions are likely specific for each ligand, general spotting conditions 
were found to work sufficiently well for a number of proteins.   
 
Conditions that included ligands at a 0.1-1 mg/ml concentrations in a phosphate buffered 
saline (PBS) solution containing 1-2% glycerol and 1-2% D(+) trehalose were found to 
consistently provide reasonable spot morphology while maintaining ligand activity.  After 
spotting, chips are incubated at room temperature overnight.  Chips are briefly washed and 
blocked using a solution of 1% BSA (m/v), 0.1% tween-20 in 1X PBS (1% BSA/PBST), 
then dried gently using a clean, inert gas (N2).  See the Appendix for additional details on 
spotting conditions. 
 
Performing a typical IRIS assay 
After washing, blocking and drying the IRIS chip, the chip is loaded into the IRIS system 
by assembling the microfluidic chamber (see Figure 5) and loading onto the stage (see 
Figure 6).  Buffer (1% BSA/PBST) is flowed through the chamber to reach equilibrium 
prior to running the assay.   
 
The LED’s and the camera acquisition software are turned on and the appropriate settings 
are verified.  Prior to running the assay, the data acquisition is tested to ensure that the 
appropriate quality and time points are established.  Additionally, background drift is 
evaluated prior to running the assay to ensure that the chip has reached a steady state prior 
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to beginning the experiment. 
 
Typical binding studies will run buffer only for 5–10 minutes before injecting the analyte.  
The analyte is prepared by diluting the stock solution in 1% BSA/PBST to a final concen-
tration of 1-10 µg/ml.  After the analyte is injected into the chip for 5-10 minutes to record 
the association phase, buffer is subsequently injected over the chip surface to acquire the 
dissociation phase.  Buffer may be run for 20–60 minutes in order to acquire the slower 
dissociation phase.  Additional steps may be incorporated at this time, including sandwich-
ing antibody steps, depending upon the nature of the experiment.  Specific assay steps and 
procedures are indicated with the relevant experiments for additional clarity. 
 
Data collection 
The reflected light intensity is measured at the camera and the data is processed at the 
computer using ImageJ (Micromanager suite) (Edelstein, et al., 2014).  As described and 
demonstrated elsewhere (Avci, Ünlü, Özkumur, & Ünlü, 2015) (Özkumur, et al., 2008), if 
multiple wavelengths are used it is possible to approximate the nanometers (nm) of thick-
ness (or 𝑝𝑔/𝑚𝑚2) for a given spot at the silicon oxide surface (with the approximation 
that the spotted ligand has a similar refractive index as the oxide surface).  Significant 
computational improvements were previously made to this methodology by the creation of 
a ‘look-up’ table and the use of a 4-color LED illumination source (Daaboul, et al., 2011). 
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However, it is experimentally and computationally simpler to use a single wavelength (blue 
LED, λD = 460 nm), particularly as the signals generated using the blue LED are approxi-
mately directly proportional to the increase in thickness at the sensor surface.  The deter-
mination of the binding parameters, 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓, are not dependent upon the units used 
in the measurement method (e.g., SPR uses “Response Units, RU”), with the underlying 
assumption that the units are directly proportional to the concentration of analyte bound to 
the surface. 
 
To this end, the data collected here is presented as a single wavelength measurement of the 
light intensity (“Reflectivity”) and is either presented as “Signal (AU)” or, similarly, “Re-
flectivity (AU)”.  Four color LED measurements were taken of the chip in buffer prior to 
initiating most experiments; in this way, it is possible to retroactively estimate units in 
terms of 𝑝𝑔/𝑚𝑚2, as desired.     
 
Each time point is effectively a single image of the entire field of view (~4.2mm x 3.5mm 
using a 2X objective).  During the time course of the experiment, a sequential series of 
images are collected and used to create an image stack.  It is noteworthy that individual 
spots for each ligand are visible on the camera (dependent upon the MW of the ligand), 
real-time, while submerged in buffer in the microfluidic chamber.   
 
The actual signal for the binding curves are then simply the mean pixel values for the re-
gions inside the spot minus the mean pixel values for a nearby reference area (just outside 
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of the spot – see Figure 9 for reference).  This method accounts (to a large degree) for the 
fluctuations and drift in LED illumination intensity and spatial illumination variability on 
the chip surface itself.  In addition, relevant control spots (e.g., BSA or unrelated monoclo-
nal antibodies) are included in the spotting protocols.  Signals generated at the negative 
control spots may account for additional non-specific binding that may occur either with 
the ligand itself or the chip surface.  For calculations of the kinetic parameters, any signals 
generated with the negative control spots are also subtracted from any true signal response 
such that the captured signals are representative of true ligand-analyte interactions.   
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Figure 9.  An example ‘difference image’ of a scanned, spotted chip loaded into the IRIS 
instrument (and submerged in buffer) is shown here.  Each spot size is ~300 µm in diameter.  
The ‘difference image’ represents the raw data at any given time point minus the raw data 
collected at time t = 0 seconds.  The red circle indicates a typical region of interest within 
the spot while the green area represents a reference region.  The recorded signal (“Signal 
(AU)”) is simply the mean of the pixel values within the red region minus the mean of the 
pixel values within the green region. 
 
In addition to collecting the actual binding curves for each spotted ligand, a binding movie 
can be created that is simply made from the concatenation of all the collected image time 
points.  This binding movie (or “difference movie”) uses the first image in the series as a 
reference (“blank”) and this reference image is effectively subtracted from each of the sub-
sequent images in the image stack.  The chip then starts as a blank surface at t = 0 sec and, 
as binding events occur, the spots that visually appear are proportional to the amount of 
~3.5mm 
~4.2mm 
Example IRIS ‘difference’ image 
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binding that takes place for a given ligand.  This provides a relatively quick method to ‘see’ 
which ligands bind best to a given analyte as it is injected over the chip surface.  
 
Occasionally, slices from these collected image stacks are presented in order to provide 
some visual reference for the binding curve data sets.  It should be understood, however, 
that these image slices are just a subset of the complete image stack and full binding movies 
are created with each experiment that is performed.  An example selection of image slices 
from a binding event is shown in Figure 10 for reference. 
 
 
 
 
 
 
 
Figure 10.  Example slices of the ‘difference’ movie is shown at different time points during 
a typical binding experiment.  All slices represent the raw intensity value minus the data 
collected at t = 0 seconds.  (a) The initial slice is just prior to any binding events occurring. 
(b) The increased spot intensity is indicative of mass accumulation at each spot.  (c) Near 
the end of the experiment, equilibrium levels are reached.  Increased signals at the spot 
region of interest (ROI) are indicative of accumulated mass during the time course of the 
experiment.  This data set was collected as part of a lethal factor (LF) binding experiment; 
see Figure 15 and surrounding text for reference. 
 
Time 
Sample Image Slices 
(a) (b) (c) 
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Using the ImageJ with Micromanager software suite, it is possible to adjust the number of 
averaged frames, the time points for data collection, the exposure time, etc.  For data pre-
sented here, typically 90 frames were averaged, with each frame collected at 100 msec 
intervals.  The average of these 90 frames was then used as a single image time point to be 
added as an image slice in the stack.  Therefore, one image was effectively added to the 
data set every 9 sec (90 frames x 100 msec intervals).  While additional frames and more 
frequent time points are possible, these settings were found to provide a balance between 
the experimental noise, frequency of data points and file size.  
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Chapter 4 Kinetic binding analysis 
 
Langmuir binding model: 
It is of some relevance to review the most commonly used analytical tools as applied to 
real time ligand-analyte binding events.  Of course, the most frequently applied method for 
evaluating affinity characteristics of ligands (e.g., antibodies), is the 1:1 or Langmuir bind-
ing model.  This “pseudo-first order binding” model considers one ligand [𝐿] can only 
associate with one analyte [𝑅] and does so in a reversible manner, such that [𝐿] + [𝑅] ↔
[𝐿𝑅] in a dynamic state.  The absolute concentrations of bound and free analyte will con-
stantly be in flux until equilibrium is reached. 
 
Now, if the dynamic signal, 𝑠(𝑡), of the given sensor (e.g., SPR, BLI, IRIS, etc.) may be 
considered as approximately proportional to the concentration of surface bound analyte 
(that is, [𝐿𝑅]), then we may estimate the rate of bound material to the following first order 
differential equation (Schuck & Zhao, 2010) (Karlsson, Michaelsson, & Mattsson, 1991): 
 
𝑑𝑠
𝑑𝑡
∝  
𝑑[𝐿𝑅]
𝑑𝑡
= 𝑘𝑜𝑛[𝑅][𝐿] −  𝑘𝑜𝑓𝑓[𝐿𝑅]    (2) 
   
where [𝑅] is the concentration of free analyte (usually considered a constant as this is in 
significant excess) and [𝐿] is the concentration of unbound ligand on the sensor surface.  
As [𝐿] can be re-written as [𝐿𝑅]𝑚𝑎𝑥 − [𝐿𝑅], where [𝐿𝑅]𝑚𝑎𝑥 is the total number of surface 
sites that may bind to the analyte, we can then re-write the above as: 
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𝑑𝑠
𝑑𝑡
∝  
𝑑[𝐿𝑅]
𝑑𝑡
= 𝑘𝑜𝑛[𝑅]([𝐿𝑅]𝑚𝑎𝑥 − [𝐿𝑅]) −  𝑘𝑜𝑓𝑓[𝐿𝑅]   (3) 
  
A closed form solution of this equation is readily found using standard methods (Zill & 
Cullen, 1997).  However, it is instructive to note that when the injected analyte is removed 
(during the dissociation phase), [𝑅] → 0 and (3) reduces to a simple first order differential 
equation with a simple exponential decay with a time constant of 𝑘𝑜𝑓𝑓.  
 
To simplify and to maintain consistency, we will us the nomenclature specified in (Schuck 
& Zhao, 2010).  (3) may then be re-written as: 
 
𝑑𝑠
𝑑𝑡
= 𝑘𝑜𝑛𝑐(𝑠𝑚𝑎𝑥 − 𝑠) −  𝑘𝑜𝑓𝑓𝑠   (4) 
 
where we keep in mind that 𝑐 refers to the concentration of the analyte injected over the 
chip, 𝑠 now refers to the surface bound analyte concentration (“[𝐿𝑅]”) and 𝑠𝑚𝑎𝑥 is the 
maximum number (concentration) of analyte that may be bound to the surface. 
 
By solving (4), we may then see that after the chip is exposed to the analyte for a given 
time, 𝑡, the time and concentration dependent association phase may be expressed as: 
 
𝑠𝑎(𝑐, 𝑡) =  
𝑠𝑚𝑎𝑥
1+(
𝑘𝑜𝑛𝑐
𝑘𝑜𝑓𝑓
)−1
(1 − 𝑒−(𝑘𝑜𝑛𝑐+𝑘𝑜𝑓𝑓)(𝑡−𝑡0))   (5) 
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the association We note that as 𝑡 → ∞,phase signal will approach the steady-state value of: 
 
𝑠𝑒𝑞(𝑐) =  
𝑠𝑚𝑎𝑥
1+(
𝑘𝑜𝑛𝑐
𝑘𝑜𝑓𝑓
)−1
   (6) 
 
Where we note that the traditional 𝐾𝐴 = 𝐾𝐷
−1 =
𝑘𝑜𝑛
𝑘𝑜𝑓𝑓
.  We also observe that (5) may be 
simplified to: 
 
𝑠𝑎(𝑐, 𝑡) =  𝑠𝑒𝑞(1 − 𝑒
−(𝑘𝑜𝑛𝑐+𝑘𝑜𝑓𝑓)(𝑡−𝑡0))   (7) 
 
After the analyte has passed over the chip, buffer may then be injected into the flow cell 
such that the concentration, 𝑐, rapidly goes to 0 (dissociation phase).  In this case, the so-
lution to (4) immediately simplifies to: 
 
𝑠𝑑(𝑐, 𝑡) =  𝑠𝑎(𝑐, 𝑡𝑐)𝑒
−𝑘𝑜𝑓𝑓(𝑡−𝑡𝑐)   (8) 
 
Figure 11 shows some example simulated binding curves using 𝑘𝑜𝑛 = 1𝑥10
5𝑚𝑜𝑙−1𝑠−1, 
𝑘𝑜𝑓𝑓 = 3𝑥10
−3𝑠−1 with varying concentrations of analyte.   
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Figure 11.  Sample 1:1 binding curves generated using (7) and (8) are shown above.  As 
can be seen, the increasing concentrations of analyte impact the immediate rate of binding 
and the equilibrium signal that is reached. 
 
However, as noted in (Schuck & Zhao, 2010), few – if any – binding events observed via 
biosensors (e.g., SPR) are governed by true first-order (1:1) dynamics.  Typically, more 
sophisticated analyses must be applied that take into account a more complicated reality at 
the sensor surface in a flow cell.  To that end, the following sections briefly review some 
more sophisticated modeling methods that may be applicable for the IRIS system depend-
ing upon the experimental design. 
 
Bivalent model: 
Often, ligand-analyte binding pairs are formed via monoclonal antibody (mAb) and antigen 
interactions.  In these cases, one may suppose that a more realistic model of the binding 
Simulated 1:1 binding curves 
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events occurring at the sensor surface should incorporate both the binding of the first Fab 
fragment of the mAb to the analyte as well as the binding of the second Fab fragment of 
the mAb to a second analyte.  That is, a bivalent antibody may bind to two separate circu-
lating antigens and it is certainly possible – if not likely – that the binding of antigen to one 
Fab fragment may directly impact the efficiency of binding to the other Fab fragment.   
 
In the bivalent scenario, we may consider the following model (Cooper & Williams, 1999): 
 
                                 (9) 
 
where two forward rate constants, 𝑘𝑎1 and 𝑘𝑎2 drive the forward binding reactions and, 
likewise, 𝑘𝑑1 and 𝑘𝑑2 drive the reverse reactions.   
 
The behavior of the system can then be described by the set of differential equations: 
 
𝑑[𝐿𝑅]
𝑑𝑡
= (2𝑘𝑎1[𝐿][𝑅] − 𝑘𝑑1[𝐿𝑅]) − (𝑘𝑎2[𝐿𝑅][𝑅] − 2𝑘𝑑2[𝐿𝑅𝑅])    (10) 
 
𝑑[𝐿𝑅𝑅]
𝑑𝑡
= 𝑘𝑎2[𝐿𝑅][𝑅] − 2𝑘𝑑2[𝐿𝑅𝑅]   (11) 
 
The above system can be solved in a closed form solution (however inefficiently).  For 
analysis of the binding constants in a bivalent model system, therefore, we numerically 
[𝐿] + 2[𝑅] ↔ [𝐿𝑅] + [𝑅] ↔ [𝐿𝑅𝑅]  
  
𝑘𝑎1 𝑘𝑎2 
𝑘𝑑1 𝑘𝑑2 
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solved the system of differential equations for the sake of computational efficiency 
(Causon & Mingham, 2014).  See (Cooper & Williams, 1999) for additional reference.   
 
Mass transport limited model: 
This brief introduction to the mass transport limited (MTL) model follows the reasoning 
and notation as elucidated in (Schuck & Zhao, 2010) and (Glaser, 1993).  Under MTL 
conditions, a depletion zone is formed where the analyte concentration near the surface-
bound ligands is lower than the bulk analyte concentration.  That is, the analytes near the 
ligands at the surface are depleted more rapidly than can be replenished by the governing 
diffusion kinetics of the analyte in solution.  A concentration gradient is formed which 
“diminished continuously with time as steady-state is attained.  Unless the life-time of these 
gradients is much faster than the time-scale of the chemical kinetics, they will have pro-
found influence on the observed binding kinetics.” (Schuck & Zhao, 2010).  Of significant 
import, in order to reduce the influence of MTL on experimental design, two primary op-
tions are available: (1) Reduce the ligand concentration on the functionalized surface (alt-
hough this may reduce the magnitude of the observed signal) or (2) Increase the flow rate 
of the injected analyte (although this only improves the diffusion limitations by the cubic 
root of the flow rate – if the flow rate is increased by 8X, the diffusion limits are only 
improved by a factor of 2X).   
 
A two-compartment model may be generated that simplifies the physical situation into a 
region close to the surface, with a diffusion-limited concentration of analyte near the 
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surface, 𝑐𝑠𝑢𝑟𝑓, and a bulk analyte concentration, 𝑐, some distance removed from the surface 
that transports molecules to the surface at a rate 𝑘𝑡𝑟.   
 
As can be seen in the following equations, we may now estimate the rate of change of the 
concentration in the “surface” compartment as proportional to the concentration gradient 
minus the amount of analyte that becomes bound to the surface.  Likewise, the modified 
rate equation, (13), now incorporates this time-dependent concentration near the surface in 
place of a fixed bulk analyte concentration. 
 
𝑑𝑐𝑠𝑢𝑟𝑓
𝑑𝑡
= 𝑘𝑡𝑟(𝑐 − 𝑐𝑠𝑢𝑟𝑓) −
𝑑𝑠
𝑑𝑡
             (12) 
 
𝑑𝑠
𝑑𝑡
= 𝑘𝑜𝑛𝑐𝑠𝑢𝑟𝑓(𝑠𝑚𝑎𝑥 − 𝑠) − 𝑘𝑜𝑓𝑓𝑠              (13) 
 
While the simplistic two-compartment model may not provide a full picture of the events 
happening at the sensor surface, key behaviors should be understood when numerically 
solving the above, as described in (Schuck & Zhao, 2010).  In particular, with mass-
transport limited (MTL) cases, slower apparent on and off kinetic rates should be expected.   
 
Heterogenous surface model: 
Additional considerations may be given to the fact that the sensing surface itself is, in all 
probability, not completely uniform.  Variations in ligand attachment sites, orientations, 
density, microenvironment, etc., may contribute significantly to a continuum of binding 
activities.  The observed signal would then be the sum of the individual contributions of 
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this continuum of 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates. 
 
The equation estimating the signal observed is reproduced here without derivation [see 
(Schuck & Zhao, 2010) for reference]:    
 
𝑠𝑡𝑜𝑡(𝑐, 𝑡) =  ∫ ∫ 𝑠1(𝑘𝑜𝑓𝑓 , 𝐾𝐷 , 𝑐, 𝑡)𝑃(𝑘𝑜𝑓𝑓 , 𝐾𝐷)𝑑𝑘𝑜𝑓𝑓𝑑𝐾𝐷
𝑘𝑜𝑓𝑓,𝑚𝑎𝑥
𝑘𝑜𝑓𝑓,𝑚𝑖𝑛
𝐾𝐷,𝑚𝑎𝑥
𝐾𝐷,𝑚𝑖𝑛
          (14) 
 
This equation is implemented in the Evilfit software package (see the following section, 
Chapter 5 Software for kinetic analysis).  As can be seen, the 𝑘𝑜𝑓𝑓 and 𝐾𝐷 parameters are 
integrated over a range of possible values.  The 𝑠1 term is the binding signal observed for 
each given 𝑘𝑜𝑓𝑓 and 𝐾𝐷 while 𝑃(𝑘𝑜𝑓𝑓, 𝐾𝐷) is “the two-dimensional distribution of affinity 
and rate constants.”  For additional details, please see (Schuck & Zhao, 2010).   
 
Conclusion: 
The analysis of the kinetic parameters from the measured raw data is a fundamental portion 
of label-free sensing.  Here, we have reviewed some of the key approaches to measuring 
and quantifying the performance of any given ligand.  These approaches include the tradi-
tional Langmuir (1:1) binding model and a bivalent binding model.  The mass-transport 
limited (MTL) model was also reviewed and it is directly understood how the MTL condi-
tions will dominate high affinity interaction binding events and that the need to monitor 
and mitigate these potential conditions is significant.  The inhomogeneous surface model 
was briefly presented in the context of understanding that this model is applied in the Evilfit 
software package discussed in Chapter 5.  
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Chapter 5 Software for kinetic analysis 
As the raw data for the IRIS binding curves are collected, it is necessary to use an appro-
priate software analysis package to quickly and reliably determine binding constants and 
visualize the binding events.  Limited free software packages are available for such anal-
yses and are typically limited freeware versions and are designed specifically for SPR 
measurements (e.g., BioLogics Scrubber v2 package).  Often, commercial entities 
(ForteBio, Biacore, etc.) provide proprietary software dedicated specifically to their plat-
form.  As neither of these approaches were deemed suitable for the rapid and parallel anal-
ysis that is required, two separate approaches were pursued.  First, a custom python-based 
script was created to perform Langmuir and bivalent fit models to an arbitrarily large data 
set (memory limited only).  Second, a MATLAB based software package created by Peter 
Schuck, et al. (Schuck & Zhao, 2010) (Svitel, Balbo, Mariuzza, Gonzales, & Schuck, 2003) 
was used for comparison and better understanding of potential rate distributions given sur-
face inhomogeneities.   
 
Custom python script and GUI: 
In order to quickly visualize and evaluate the performance of a number of simultaneously 
tested ligands, it is necessary to use a corresponding software package customized to the 
data that is generated.  A necessary package should include the ability to load multiple 
traces and easily select the regions for association and dissociation, particularly given that 
the times of association and dissociation will be identical for the multiple ligands on a given 
IRIS chip. 
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As mentioned earlier, most binding analysis software packages are part of a commercially 
produced machine (e.g., Biacore, BioForte) and are tailored to the specific types of data 
generated by the device.  Some software (e.g., Scrubber v2) can be evaluated but is tailored 
for SPR measurements and requires purchase of the software for commercial purposes.  In 
the case of the IRIS, it is desirable to have the ability to (1) load many binding curves 
simultaneously (2) as the association and dissociation time periods are identical for every 
part of the chip, these parameters should be quickly set and identical for each ligand in the 
same experiment (3) the analyte concentrations should apply identically to each curve (4) 
not be limited to MATLAB  or other proprietary software and (5) provide some methods 
for de-noising, filtering and application of Langmuir and bivalent fits. 
 
To this end, a python GUI package was created to quickly load a space-delimited text file 
data set containing all of the binding curves obtained from IRIS.  Sliders and text inputs 
were provided to quickly set the association and dissociation time points.  Check boxes to 
remove outliers in the data set, apply a filter and select the solution type (1:1 or bivalent) 
were created.  Initial parameters (‘guesses’) for the fits are required, as is the concentration 
of the analyte (M) that is being injected over the chip. 
 
A screenshot of the package is shown in Figure 12 with an example data set.  The solutions 
that are found with the software (applying the selected model) are then appended to a text 
file. 
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Figure 12.  The created Python package is shown here.  Sliders are adjustable to indicate 
the injection time points.  Outlier removal, filtering and model selection are quickly applied 
to multiple binding curves.  Vertical lines indicate the injection time points (analyte and 
buffer) and end time point of the assay. 
 
To validate the analysis of the 1:1 binding on and off rate parameters, a separate python 
script was created to generate a series of simulated binding curves that simply apply the 
equations shown in (7) and (8) with a uniform random noise added to the simulated signal.  
This simulated noisy data set was then loaded into the GUI-based solver, the start and stop 
times defined, and the 1:1 fits were solved in a so-called ‘global fit’ format (accounting for 
both association and dissociation steps simultaneously) while using the built in Levenberg-
Marquardt (LM) algorithm (via the “scipy” package using the “curve_fit” function).  The 
Custom GUI developed for rapid data analysis 
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simulated curves, the ‘noise-added’ curves and the best-fit curves are shown in Figure 13 
while the best-fit parameters are shown in Table 1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  The original simulated model data is shown in (a).  Random uniform noise was 
added to the signal to generate a simulated noisy data set in (b).  The noisy data set was 
then loaded into the custom python software and solved for the fit parameters using a 1:1 
Langmuir model.  Vertical lines indicate the injection time points (analyte and buffer) and 
end time point of the (virtual) assay. 
 
 
Simulated noisy data sets with subsequent 1:1 fit models 
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Table 1.  The parameters used to generate the ideal curves are shown above (“Simulated 
data”).  The results from loading and solving the ‘noisy’ data set (see Figure 13) with the 
custom python script are shown in the “Fit parameter” column.  
 
As can be seen, the larger the noise is relative to the observed signal, the greater the error 
in the solved parameters relative to the true parameter values.  Values for 𝑘𝑜𝑛 were varied 
from 1𝑥104𝑀−1𝑠−1 to 5𝑥105𝑀−1𝑠−1  while 𝑘𝑜𝑓𝑓 values were varied from 1𝑥10
−4𝑠−1 to 
5𝑥10−3𝑠−1.  Errors for the fit 𝐾𝐷 ranged from 0.54% - 89.3%.  As noted in (Schuck & 
Zhao, 2010), it is preferable (if not ideal) to have signal-to-noise ratios approaching 100:1 
so that proper fits can be applied and the appropriateness of the model to the collected data 
may be ascertained.  It is not surprising, therefore, that such large errors in the fit parame-
ters are apparent when the noise floor is approaching the magnitude of the signal itself. 
 
Evilfit: 
A more sophisticated software package was kindly provided by Peter Schuck (Schuck & 
Zhao, 2010) that applies the heterogenous surfaced model analysis to estimate a distribu-
tion of 𝐾𝐷 and 𝑘𝑜𝑓𝑓 values.  A screenshot of the software is shown in Figure 14.  Several 
  Simulated data Fit parameters 
Rea-
gent 
𝑘𝑜𝑛 (𝑀
−1𝑠−1) 𝑘𝑜𝑓𝑓 (𝑠
−1) 𝐾𝐷 (𝑀) 𝑘𝑜𝑛 (𝑀
−1𝑠−1) 𝑘𝑜𝑓𝑓 (𝑠
−1) 𝐾𝐷 (𝑀) 
% Error 
in 𝐾𝐷 
S_0: 1.00E+04 1.00E-04 1.00E-08 6.00E+03 1.14E-04 1.89E-08 89.33% 
S_1: 5.00E+04 5.00E-04 1.00E-08 4.94E+04 5.17E-04 1.05E-08 4.60% 
S_2: 1.00E+05 1.00E-03 1.00E-08 9.99E+04 9.91E-04 9.92E-09 -0.79% 
S_3: 5.00E+05 5.00E-03 1.00E-08 4.98E+05 5.01E-03 1.01E-08 0.54% 
Evaluating accuracy of fit parameters 
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options are available, including settings for baseline values, on and off times, regions to 
integrate with the ability to load multiple analyte concentrations.  For application to data 
collected with the IRIS, only the simplest of options were evaluated here, allowing both 
association and dissociation curves (from replicate spots) to have individual baselines and 
defining the confidence level at 0.95.  Peaks were manually integrated to obtain a mean 
point value to compare to reported results. 
 
While this software package was found to provide a very sophisticated approach to analyz-
ing and estimating the kinetic parameters, the user interface for analyzing multiple unique 
ligands simultaneously was significantly more cumbersome and tailored to SPR data.  Ad-
ditionally, while the Evilfit analysis may, in fact, be more representative of the ‘true’ nature 
of the heterogeneity of the surface and the distribution of activities present at the surface, 
published data for most reagents is most often limited to 1:1 or simple bivalent models with 
very little account given for distributions of kinetic parameters.  To this end, the Evilfit 
software package was limited to only evaluating select IRIS binding curves obtained with 
ligands that have published kinetic results and subsequently compared with fit results from 
the python GUI software package.  
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Figure 14.  A screenshot of the Evilfit software package is shown here. Note how a 
distribution of potential on and off rates are estimated.  It is possible to integrate a 
manually selected region to find effective 𝑘𝑜𝑓𝑓 and 𝐾𝐷 values. 
 
  
Exemplary screenshot using Evilfit software package 
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Chapter 6 Validation of binding kinetics 
In order to understand the significance of the reactions observed at the chip surface, it is 
desirable to validate the binding characteristics obtained with IRIS and compare these to 
reported results that used other techniques (SPR, BLI, etc.).  Unfortunately, SPR and BLI 
instrumentation are not available in-house and direct comparisons that use identical 
experimental design were not possible (e.g., identical buffers, identically sourced reagents, 
chemical linkage, etc.).  However, InBios International, Inc. generously provided a variety 
of reagents that have been qualified with either SPR or BLI with published results 
available.  These reagents represent two different disease states (anthrax and zika) and 
ligand types (camelid VHH and mouse monoclonal antibodies). 
 
To that end, we performed IRIS binding experiments and compared the results obtained 
with IRIS to the published SPR and BLI data sets.  Reference testing for lethal factor (LF) 
binding was performed with SPR while reference testing for Zika envelope protein was 
performed with BLI instrumentation.  Comparisons of 1:1 and bivalent fit models are 
shown in the context of the tested anthrax and zika ligands.   
 
Lethal factor binding: 
Bacillus anthracis is the Gram-positive bacterium that is the causative agent of anthrax 
infection.  The key virulence factors are transcribed by the extrachromosomal plasmid, 
pXO1, which include protective antigen (PA), edema factor (EF) and lethal factor (LF) 
(Fouet & Mock, 2006).  A significant contributor to the pathogen’s lethal toxicity is the 
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edema toxin (ETx) and lethal toxin (LTx) which are formed by the complexing of EF with 
PA and LF with PA, respectively (Liu, Moayeri, & Leppla, 2014).  The development of 
immunoassays that target lethal factor antigen may contribute to the early detection and 
diagnosis of B. anthracis exposure (Boyer, et al., 2009).  Lethal factor itself is a ~90 kDa 
protein that may be considered harmless until the LTx complex is formed. 
 
Three high affinity ligands (JMO-B9, JMO-B3, and JMO-G1) have been previously devel-
oped and evaluated at the Shoemaker laboratory using SPR (Vrentas, et al., 2016) with 
estimates of 1:1 binding kinetics that target the protein of interest, lethal factor (LF) anti-
gen, determined using SPR.  JMO-B9, JMO-B3 and JMO-G1 are single chain antibodies 
(VHH) derived from camelid antibodies selected for high affinity targeting of LF.   
 
As described in (Vrentas, et al., 2016) – as part of the process to qualify the VHHs – the 
LF antigen was coupled to the functionalized gold surface and various ligands (VHHs) 
were injected over the surface in order to obtain the real-time binding characteristics.  Trip-
licate runs were performed and representative curves were presented in the publication.  
This experimental protocol is distinctly different than the method used with IRIS, where 
VHH ligands were spotted onto the functionalized chip and LF was injected over the sur-
face.  Replicate spots were present on the IRIS chip, with each series of spots representing 
a unique ligand.  This permits replicate testing of the same ligand de facto during a single 
injection of reagent.  
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In order to evaluate the same VHH reagents with IRIS, we spotted the ligands using a 
benchtop BioRad Calligrapher with ~300 µm spot sizes and an approximate ~580 µm pitch 
directly onto an epoxysilanized IRIS chip (see Appendix).  Spotting solutions contained 
1% glycerol and 1% D(+)-trehalose to reduce spot drying, improve spot morphology and 
to aid in maintaining ligand functionality.  Spotting solutions for JMO-G1 and JMO-B3 
contained 50% glycerol as these were the stock conditions for the provided reagents.  Neg-
ative control spots included a 1 mg/ml BSA solution and an irrelevant VHH dimer pro-
duced and purified at InBios International, Inc.  After spotting, chips were incubated over-
night at room temperature before washing and blocking.  Chips were washed and blocked 
by simply pouring a solution of 1% (m/v) bovine serum albumin (BSA) in phosphate buff-
ered saline (PBS) with 0.1% polysorbate-20 (tween-20) (1% BSA/PBST), then placing the 
chip in this same buffer for 5 minutes.  The chip was then gently dried with N2, attached to 
the PSA gasket and AR glass slide, then loaded onto the IRIS stage.  A solution of 1% 
BSA/PBST was then injected over the chip.  Prior to starting the assay, a 0.1M glycine, pH 
2.5 solution was injected into the microfluidic chamber for 1 minute to remove any loosely 
bound (non-covalent) ligand from the chip surface.  The solution of 1% BSA/PBST was 
subsequently injected into the chamber to equilibrate the chip. 
 
The injection protocol was straightforward: the running buffer of 1% BSA/PBST was in-
jected for 5 minutes.  This was followed by a 10 µg/ml solution of LF antigen (~111 nM) 
diluted into 1% BSA/PBST and injected for 10 minutes.  This was followed by the running 
buffer (1% BSA/BST) for ~45 minutes to record the dissociation phase. 
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Figure 15 shows the schematic for the ligands and controls that were spotted onto the IRIS 
chip while Figure 16 shows the average binding curves that were obtained for each ligand 
type.  Additionally, images representing the ‘difference image’ at the start and end of the 
assay are shown, indicative of the direct binding that was observed at the chip surface. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15.  BSA and VHH negative control ligands were spotted in triplicate at 1 mg/ml.  
JMO-B9 dimer and monomeric forms were spotted at 1 mg/ml (in triplicate, lower set of 
three) and 0.1 mg/ml (in triplicate, the upper set of three) in the columns indicated.  JMO-
B3 and JMO-B9 were spotted at 0.76 mg/ml and 0.9 mg/ml, respectively, in replicates of n 
= 6 in the columns indicated.  The black and grey spots are an additional LF specific ligand 
that was being evaluated as part of the experiment but, as it was not included in the 
reference publication result, data for these spots are not included here for the sake of 
clarity. 
 
Spotting layout method for evaluat-
ing VHH anthrax ligands 
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Figure 16.  The mean signals obtained for the replicate spots for the various ligands are 
shown in the above figure.  The data shown here is normalized to the VHH-Dimer negative 
control; that is, the unrelated VHH ligand acts as the effective ‘reference spot’.  ‘Difference 
images’ are shown at representative time points to show the overall effective binding at 
each spot over the time course of the experiment.  Note that the 6th column in the image 
contains the negative control spots (no significant binding observed). 
 
A few observations are apparent upon careful examination of Figure 16.  First, we note that 
both the VHH negative control and BSA negative control behaved similarly and appeared 
to have no significant specific binding to the LF antigen upon injection.  Secondly, we 
notice that some curvature differences are apparent with the various ligands and 
measurable binding results are readily obtained at both 1.0 mg/ml and 0.1 mg/ml spotting 
conditions.  Additionally, we note that the JMO-B9 dimer appears to have approximately 
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twice the signal capacity as the JMO-B9 monomer; this may be indicative of a greater 
ligand density or a greater fraction of active ligands on the chip surface.  Lastly, we note 
that the apparent dissociation rates appear to be very low with very little loss in signal after 
~45 minutes of running buffer. 
 
To estimate the on and off rates (𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓), binding curves were normalized to the 
negative control VHH.  That is, the signal measured for the VHH negative control at each 
time point is simply subtracted from the corresponding ligand signal time point.  This 
‘normalized’ data set (akin to using a flow cell control in SPR measurements) is then used 
for estimates of the kinetic parameters.  Applying this approach may help ameliorate 
problems that arise due to issues of non-specific binding (e.g., passive adsorption) to the 
spot and background regions. 
 
The measured signals for the individual replicates for JMO-G1 are shown in Figure 17.    
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Figure 17.  The raw data for the observed binding curves for the individual JMO-G1 spots 
are shown above.  In addition, the fit 1:1 Langmuir binding curves for each replicate spot 
are shown.  It is apparent that the binding model applied here may not provide the best 
goodness-of-fit given the characteristics of the fit curve relative to the raw data; however, 
as this 1:1 model was used in the SPR publication that evaluated these ligands, we will 
compare the fits obtained here using the same model. 
 
It is noted that the curvature in Figure 17 seems similar for each of the replicate spots and 
it is not unreasonable to consider that each spot may differ from one another by a straight-
forward multiplicative scale factor.  This may be explicable by considering that the effec-
tive density in each spot may differ or that the selected regions of interest may be hetero-
genous.  Additionally, variations in raw light intensity across the entire chip may also con-
tribute to some spot-to-spot variability.  Nonetheless, the increasing signal over the back-
ground should be proportional from one spot to the other.  A straightforward attempt to 
normalize each spotted replicate (to the mean peak value in each curve) is shown in Figure 
18. 
 
 
JMO-G1 Replicate Binding Curves using IRIS 
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Figure 18.  The replicate spots for JMO-G1 are shown here after the application of a simple 
normalizing scale factor (multiplicative – based upon the peak value in the binding curve).   
 
Likewise, the individual replicate spots for JMO-B3 are shown in Figure 19.   
 
 
 
 
 
 
 
 
Figure 19.  The individual replicate spot data generated for JMO-B3 is shown here.  The 
shape and behavior for each curve appear similar. 
 
JMO-G1 Replicate Binding Curves using IRIS - Scaled 
JMO-B3 Replicate Binding Curves using IRIS 
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As done with the JMO-G1 spots, the replicate curves were normalized to the peak values 
and a multiplicative scale factor is applied.  The results for scaling the curves are shown in 
Figure 20.   
 
 
 
 
 
 
 
 
Figure 20.  The replicate binding curves for JMO-B3 are shown here after applying a 
simple normalizing scale factor (multiplicative – based upon the peak value of the binding 
curve).   
 
As noted above, the JMO-B9 did not produce measurable binding characteristics with SPR 
and the authors had supposed that the epitope present on LF was not available for binding 
with the JMO-B9 once the antigen had been covalently bound to the SPR surface.  How-
ever, the authors were able to confirm the specific high reactivity of JMO-B9 to the LF 
antigen via ELISA. 
 
JMO-B3 Replicate Binding Curves using IRIS - Scaled 
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With the IRIS system, it is possible to measure the kinetic characteristics of the JMO-B9 
with the ligand spotted onto an epoxysilanized surface.  It was also found possible to meas-
ure the kinetic binding in the reverse format, with the LF antigen spotted directly onto the 
chip surface (data not shown).  The data for the replicate spots for the 1.0 mg/ml JMO-B9 
VHH monomeric ligand is shown in Figure 21. 
 
Figure 21.  The raw data and 1:1 fit binding curves for JMO-B9 are shown for the 1.0 
mg/ml spots of JMO-B9 ligand.  Similar kinetic parameters were obtained for the 0.1 mg/ml 
spots (𝐾𝐷~3.0𝑥10
−10 𝑀). 
 
For reference, the binding curves obtained by Vrentas et al. (2016), are reproduced here in 
Figure 22.  We note that the overall behavior of the curves for JMO-G1 and JMO-B3 are 
similar to those obtained via IRIS even given the differences in experimental setup and 
protocol (e.g., fast on-rates, a very low apparent off-rate, etc.). 
  
JMO-B9 Replicate Binding Curves using IRIS 
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Figure 22.  The binding curves obtained via SPR by Vrentas et al. (2016) are reproduced 
here.  Binding to LF antigen is shown in the grey solid circles for JMO-G1 (a) and JMO-
B3 (b).  (This research was originally published in the Journal of Biological Chemistry, 
(Vrentas, et al., 2016) © the American Society for Biochemistry and Molecular Biology.) 
 
The fit curves (1:1) for the JMO-G1 and JMO-B3 ligands were not provided as part of the 
reference data – an unfortunately common characteristic in many publications with SPR 
and BLI supporting data.   
 
The summary binding parameters that were found using the 1:1 Langmuir model with the 
JMO-G1, JMO-B3 and JMO-B9 ligands are shown in Table 2 and are compared directly 
to the values found in the reference publication. 
 
 
 
 
 
(a) (b) 
JMO-G1 and JMO-B3 Replicate Binding Curves using 
SPR (Vrentas, et al., 2016) 
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Table 2.  The fit parameter values (1:1 Langmuir binding model) using the IRIS system are 
compared directly to the published values (Vrentas, et al., 2016) obtained via SPR.  Error 
values in the IRIS measurement represent ±1 standard deviation from the mean value from 
replicate spots (not the error in the fit itself).  Fits were determined and applied to the raw 
data shown in Figure 17, Figure 19 and Figure 21.   
 
Now, it is quite apparent from Figure 17, Figure 19 and Figure 21 that the simple 1:1 fitting 
paradigm is likely not a sufficiently sophisticated model to accurately represent the binding 
kinetics that are occurring at the chip surface.  Indeed, a close-up comparison of the Lang-
muir to the bivalent fit models is shown in Figure 23.   
 
 
 
 
 
 
 
  PUBLISHED PARAMETER 
VALUES 1:1 FIT (VRENTAS, ET 
AL., 2016) 
IRIS KINETIC PARAMETERS 1:1 
FIT 
REA-
GENT 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷  
(𝑀) 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷  
(𝑀) 
JMO-B3 (7.7 ± 1.5) 𝑥105 (7.6 ± 0.5) 
𝑥10−6 
(2.0 ± 0.5) 
𝑥10−11 
(1.4 ± 0.13) 𝑥105 (5.0 ± 2.5) 
𝑥10−6 
(3.6 ± 1.5) 
𝑥10−11 
JMO-B9 N/A N/A N/A (7.5 ± 0.62) 𝑥104 (1.5 ± 0.32) 
𝑥10−5 
(2.0 ± 0.6) 
𝑥10−10 
JMO-G1 (5.5 ± 0.6) 𝑥105 (6.6 ± 3.0) 
𝑥10−6 
(1.1 ± 0.5) 
𝑥10−11 
(1.33 ± 0.17) 
𝑥105 
(4.4 ± 1.9) 
𝑥10−6 
(3.3 ± 1.8) 
𝑥10−11 
JMO-G1 and JMO-B3 Replicate Binding Curves using 
SPR (Vrentas, et al., 2016) 
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Figure 23.  The Langmuir (1:1) fit line is shown in solid orange, above, while the bivalent 
fit model is shown in solid green.  The bivalent fit model provides a better fit (less error) to 
the experimental data (solid blue circles).   
 
While the bivalent fit model does appear to have a better overall fit, this may be indicative 
of the presence of a secondary exponential component influencing the binding kinetics 
(potentially a heterogenous surface and/or diffusion limitations) rather than evidence that 
the bivalent model is a better representation of the actual physics of binding at the chip 
surface. 
 
For comparison, we also evaluated the fits for JMO-B3 and JMO-G1 ligands using the 
Evilfit software package.  Replicate spots of each ligand were loaded into the software 
Comparison of 1:1 vs. bivalent fits 
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package at a fixed concentration.  Dissociation and association baselines were set at ‘indi-
vidual’ and the confidence interval maintained at 0.95.  After the distribution of 𝑘𝑜𝑓𝑓 and 
𝐾𝐷 values were obtained, a manually drawn region of interest around the peak was created in order 
to estimate mean kinetic parameters.  A screenshot of the fit curves and parameters for JMO-B3 is 
shown in Figure 24. 
 
 
 
 
 
Figure 24.  A screenshot of the Evilfit software package showing the distribution and fit 
curves obtained.  The light red line in the distribution image indicates the integrated region 
of interest used to generate mean 𝐾𝐷 and 𝑘𝑜𝑓𝑓 values. 
 
Evilfit results using JMO-B3 ligand 
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Likewise, a screenshot showing the distribution of binding results obtained with JMO-G1 
is shown in Figure 25.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25.  The distribution of 𝑘𝑜𝑓𝑓 and 𝐾𝐷 values are graphically shown here, obtained 
using the Evilfit software package.  The light red line indicates the integrated region used 
to obtain the mean kinetic parameters.   
 
The mean integrated kinetic (𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓) and equilibrium (𝐾𝐷) parameters were esti-
mated by manually selecting the peak regions in the distribution.  The mean results are 
shown in Table 3 and compared directly to the published SPR (1:1 fit) values.  
  
Evilfit results using JMO-G1 ligand 
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Table 3.  The integrated kinetic parameter values, 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓 and 𝐾𝐷 are shown here in direct 
comparison to the published SPR results.  While 𝐾𝐷 values fell reasonably close (within ~2x) to the 
published results, the individual on and off rates were ~5 to ~10-fold different.  We also note that 
the final integrated 𝐾𝐷 values using the Evilfit software are also remarkably close to the simplistic 
1:1 model results (see Table 2).    
 
The Evilfit software seemed to ultimately provide very similar results for 𝐾𝐷 as the more 
simplistic 1:1 model (see Table 2 and Table 3).  Given that the published results for the 
ligands studied here also used 1:1 modeling systems, further analysis and comparison is 
done solely by applying the 1:1 system with the understanding that this model is ultimately 
not ideal nor likely representative of the true physics of the problem.   However, for his-
torical and comparative purposes, it is still useful to present the fit results in this manner. 
 
Zika envelope protein: 
The Zika virus is a single stranded RNA encoded enveloped pathogen (flavivirus) with 
associations to significant birth defects and neurological symptoms in newborns (e.g., 
microcephaly) and adults (e.g., Guillain–Barré syndrome) (Driggers, et al., 2016) (Broutet, 
et al., 2016).  The Zika envelope protein (Zika E or Zika Env) is abundantly present on the 
  
PUBLISHED PARAMETER VALUES 1:1 
FIT (VRENTAS, ET AL., 2016) 
EVILFIT INTEGRATED PARAM-
ETER VALUES 
REA-
GENT 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷 
 (𝑀) 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷  
(𝑀) 
JMO-B3 (7.7 ± 1.5) 𝑥105 
(7.6 ± 0.5) 
𝑥10−6 
(2.0 ± 0.5) 𝑥10−11 1.8 𝑥104 7.36 𝑥10−7 4.06 𝑥10−11 
JMO-G1 (5.5 ± 0.6) 𝑥105 
(6.6 ± 3.0) 
𝑥10−6 
(1.1 ± 0.5) 𝑥10−11 9.26 𝑥104 1.26 𝑥10−6 1.36 𝑥10−11 
Comparing published fit parameters vs. IRIS data 
with Evilfit solution method 
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virion surface with 180 copies of the Zika E protein and membrane protein (‘M’) on each 
viral particle surface (Kostyuchenko, et al., 2016).  The Zika E protein maintains significant 
homology to dengue virus, West Nile virus and yellow fever virus (Sirohi, et al., 2016). 
 
Two monoclonal antibodies (ZV-13 and ZV-48) developed at the Michael Diamond labor-
atory  (Zhao, et al., 2016) that target different domains of the zika virus envelope protein 
were evaluated with the IRIS platform.  These antibodies were characterized by Zhao, et 
al., in part, by using biolayer interferometry (BLI).  ZV-48 targets domain III (DIII) of the 
Zika E protein while ZV-13 targets the domain I-II (DI-II) fusion loop.  As described in 
the Experimental Procedures section of Zhao, et al., to evaluate the binding affinities of 
the antibodies they were first biotinylated, re-purified, then conjugated to streptavidin 
coated BLI tips.  Recombinant, e. coli expressed Zika DIII protein was used as the target 
analyte for ZV-48 during the binding experiment whereas the “monomeric form of the 
ectodomain of E expressed in mammalian cells” was used for the binding analysis of ZV-
13. 
 
To evaluate these antibodies using the IRIS system, the antibodies were spotted onto the 
chip surface in triplicate with ~300 µm spot sizes with ~580 µm pitch.  ZV-13 and ZV-48 
were spotted at both 1 mg/ml and 0.1 mg/ml concentrations.  Blocking and washing steps 
were performed as described in the Appendix.  After loading the chip into the IRIS system, 
a 0.1 M glycine solution was injected for 60 seconds in order to remove any loosely bound 
protein from the chip surface.  A 1% BSA/PBST solution was then injected over the chip 
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to equilibrate.  The target analyte (kindly provided by InBios International, Inc.) used was 
a purified recombinant, insect cell expressed Zika E protein with an approximate MW of 
45 kDa. 
 
To evaluate the kinetic characteristics of the ZV-13 and ZV-48 monoclonal antibodies 
(mAbs), multiple concentrations of Zika envelope protein were injected over the chip 
surface.  Each concentration of envelope protein was injected (association stage) for 10-15 
minutes (depending upon the analyte concentration).  A solution of 1% BSA/PBST was 
subsequently injected to record the antibody-antigen dissociation.  The chip was then eluted 
with a 0.1M glycine solution (pH 2.5) for 3 minutes before equilibrating the chip with 
BSA/PBST and injecting the next concentration of Zika envelope protein.  In this manner, 
a series of binding curves were obtained and subsequently aligned in order to show the 
concentration dependent impact on the observed signal and binding kinetics.  If equilibrium 
points are reached, it is also possible to infer the equilibrium 𝐾𝐷 from the generated curve 
at the multiple concentrations (see eqn. (6)), however true equilibrium was not obtained at 
the concentrations used over the given time period (see Figure 26).   
 
Four (4) different Zika Env protein concentrations were used during this testing in the fol-
lowing order: 250nM, 50nM, 10nM and 2nM.  The binding curves generated for the ZV-
48 antibody using these various concentrations are shown in Figure 26 and the binding 
curves obtained for the ZV-13 antibody are shown in Figure 27.   
 
58 
 
 
 
Figure 26.  The mean binding curves collected with ZV-48 monoclonal antibody are shown 
at 2nM, 10nM, 50nM and 250nM zika envelope protein. 
 
The inherent format of the IRIS assay permitted the parallel screening of both ZV-48 and 
ZV-13 replicate spots simultaneously for each concentration.  Times of association and 
dissociation are, likewise, identical for each condition and analyte concentration, permit-
ting rapid analysis of binding kinetics. 
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Figure 27.  Simultaneously, the same curves for ZV-13 antibody were generated as these 
antibodies were all spotted onto the same IRIS chip (see Figure 27).  As can be seen here, 
the binding curve for 250nM Zika Env appears to have a dramatically larger off-rate with 
the ZV-13 mAb.  This may be due to additional antibody sloughing off of the chip surface 
and may be indicative of the presence of non-covalently linked antibody (we note that the 
signal for the ZV-13 at the 250nM actually falls below baseline during the time course for 
the dissociation events). 
 
Due to the likely presence of some amount of non-covalently linked ZV-13 antibody, the 
second highest Zika E concentration (50nM) was used for the estimation of the kinetic 
parameters. Replicate traces (n=3) of the ZV-13 and ZV-48 antibodies are shown in Figure 
28 and Figure 30 along with the corresponding 1:1 (Langmuir) fit models.  Fits for bivalent 
models are shown in Figure 29 and Figure 31.  The summary binding characteristics of the 
1:1 fit results are shown in Table 4 and are directly compared to the published results 
obtained with BLI.   
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Figure 28.  Raw data for three replicate spots for ZV-13 antibody binding to 50nM zika 
envelope protein are shown here (solid circles).  Individual fit curves (1:1 binding) are also 
indicated in solid lines.  Vertical lines indicate the injection, association and dissociation 
phases of the assay. 
 
 
Figure 29.  Individual replicates for ZV-13 antibody binding to 50nM zika envelope protein 
are duplicated here with fit curves generated using the bivalent fit model (solid lines). 
Langmuir (1:1) fit for ZV-13 replicate mAb spots 
Bivalent fit for ZV-13 replicate mAb spots 
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Figure 30.  Raw data for three replicate spots of ZV-48 antibody binding to 50nM zika 
envelope protein are shown here (solid circles).  Fit curves (1:1 binding) are indicated with 
the solid lines.  Vertical lines indicate the injection, association and dissociation time points 
of the assay. 
 
 
 
 
Figure 31.  Individual replicates for ZV-48 antibody binding to 50nM zika envelope protein 
are duplicated here with fit curves generated using the bivalent fit model (solid lines). 
 
Langmuir (1:1) fit for ZV-48 replicate mAb spots 
Bivalent fit for ZV-48 replicate mAb spots 
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  PUBLISHED PARAMETER VAL-
UES 1:1 FIT 
IRIS KINETIC PARAMETERS 1:1 
FIT 
REA-
GENT 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷  
(𝑀) 
𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷  
(𝑀) 
ZV-13 (1.43) 𝑥104 (3.51) 𝑥10−3 (254 ± 10) 
𝑥10−9 
(1.45 ± 0.14) 
𝑥105 
(5.9 ± 1.4) 
𝑥10−4 
(4.1 ± 0.3) 
𝑥10−9 
ZV-48 (1.48) 𝑥105 (3.8) 𝑥10−3 (35 ± 0.8) 
𝑥10−9 
(1.0 ± 0.08) 𝑥105 (2.7 ± 0.3) 
𝑥10−5 
(2.6 ± 0.4) 
𝑥10−10 
 
Table 4.  The fit parameter values (1:1 Langmuir binding model) using the IRIS system are 
compared directly to the published values obtained via BLI.  Error values in the IRIS 
measurement represent ±1 standard deviation from the mean value from replicate spots 
(not the error in the fit itself).       
 
For reference, the binding curves obtained by (Zhao, et al., 2016) are reproduced in Figure 
32.  Unfortunately, the 1:1 fit binding curves were not shown.  As can be seen, the overall 
behavior of the binding curves are similar to those shown in Figure 29 and Figure 31; the 
ZV-48 binds quickly and has a slower apparent off rate while the ZV-13 antibody has a 
significantly more pronounced exponential decrease during the dissociation phase.  
  
Published fit values and IRIS 1:1 fit results 
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Figure 32.  The binding curves obtained by (Zhao, et al., 2016) using ZV-48 (a) with the 
DIII domain and ZV-13 (b) with a recombinant Zika E protein are replicated here for 
reference.  Reprinted with permission from (Zhao, et al., 2016). 
 
However, as can be seen in Table 4, the fit parameters are significantly different than what 
was found in the publication.  This could be due to several factors including (1) the ZV-48 
and ZV-13 are biotinylated prior to use with the BLI probe which may impact antibody 
functionality (2) buffers used throughout the experiments may be different leading to dif-
ferent apparent binding characteristics in the different experimental protocols (3) the target 
analyte for ZV-48 is different (DIII domain vs. the complete Zika E protein) and (4) the 
source of the zika envelope protein is different: mammalian derived antigen vs. an insect 
cell expressed zika envelope protein. 
 
(a) (b) 
BLI binding curves for ZV-48 and ZV-13 
 (reproduced figures) 
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Conclusion: 
The IRIS system provided similar 𝐾𝐷 values (within experimental error) to those obtained 
with SPR for two separate VHH ligands.  Values for 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 were somewhat lower 
than published values (see Table 2).  While 𝑘𝑜𝑓𝑓 values were within the limits of error 
(overlapping standard deviations), 𝑘𝑜𝑛 values were ~5 fold lower than published values.  
This lower apparent 𝑘𝑜𝑛 value may be due to experimental differences (the SPR experiment 
linked LF directly to the gold surface whereas VHH ligands are linked directly to the IRIS 
chip surface).  We also note that the VHH ligands have a significantly lower MW than the 
LF antigen: this may imply a difference in mobility (and reduced mass transport limita-
tions) when the VHH ligand is in solution, giving potentially higher 𝑘𝑜𝑛 values using the 
VHH as the analyte.  Nonetheless, the overall behavior and rank-order of VHH ligands 
were maintained when comparing results obtained via SPR to the data acquired with the 
IRIS system.  We also note the IRIS system was successful in recording the complete bind-
ing behavior of another VHH ligand, JMO-B9, that could not be obtained with the SPR 
system. 
 
Comparing the results obtained with the IRIS system to the BLI dataset with the Zika Env 
mAbs is, by nature, more convoluted.  Differences in experimental setup include the fact 
that both ZV-13 and ZV-48 antibodies were biotinylated to use in the BLI system.  The 
source and type of target antigens were also different: use of the e. coli derived domain-III 
antigen and a mammalian cell derived Zika Env protein were different than those used with 
the IRIS experimental protocol.  The observed 𝑘𝑜𝑛 values for ZV-48 were almost identical 
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with both the IRIS and BLI system measurements, whereas the 𝑘𝑜𝑛 values for ZV-13 were 
~10-fold greater with the IRIS system over the BLI.  The 𝑘𝑜𝑓𝑓 values for ZV-48 and ZV-
13 were both significantly lower than those observed with the BLI system (implying a 
significantly better performing antibody than previously published); it is difficult to know 
if the observed differences are due to differences in experimental setup, differences in 
MTL, buffer choices or the fact that the antibodies were biotinylated and attached to avidin 
treated tips for BLI.  Still, the rank order of the antibodies is maintained (see Table 4). 
 
Given that (1) the IRIS system gave comparable kinetic parameters (and same rank order) 
as those observed with SPR using two different ligands when experimental conditions were 
most similar and (2) the IRIS system still provided the same rank order of kinetic parame-
ters (𝐾𝐷) as obtained with BLI given more divergent experimental conditions, we may have 
some confidence in the kinetic parameters obtained with the IRIS platform and applied 
analysis.  The additional considerations that the IRIS platform was able to provide meas-
urements for the JMO-B9 ligand (whereas SPR was not - see Table 2) and that the assay 
format most closely mimics the antigen capture immunoassay format (unlabeled ligand is 
attached directly to the capture surface), we should expect to measure kinetic parameters 
that correlate directly to behavior observed in a final immunoassay format. 
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Chapter 7 Multiplexed determination of kinetic parameters 
The unique flexibility of the IRIS platform allows for natural multiplexing of both spotted 
ligands and the injection of unrelated analytes over the same IRIS chip.  The large-scale 
screening of purified ligands and the added efficiency of evaluating multiple ligand-analyte 
pairs representing different disease states provides significant utility to the researcher. 
 
Immediate feedback for analyte specific binding is possible and has been recorded; esti-
mates for the most efficient binders can be determined while the assay is running, permit-
ting the researcher to subsequently hand pick potential binding partners to flow over the 
chip and optimize for binding pairs immediately. 
 
In the following sections, we review each of these aspects of the IRIS system as well as the 
application of these results to standard immunoassay development. 
 
A brief introduction to each disease and disease relevant target is also presented to provide 
context to the collected data and the specific analytes evaluated.       
 
Screening ligands in the presence of unrelated analyte: Y. pestis and dengue 
As part of this initial screening, we evaluated multiple ligands with different target analytes 
representing two unrelated diseased states, Yersinia pestis and dengue fever. 
 
Yersinia pestis (Y. pestis), the causative agent of plague, has been responsible for waves of 
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pandemic human infection and death.  Human outbreaks are currently rare, but still occur 
and the human burden of this disease is primarily associated with contact between rodents 
and their fleas (Achtman, et al., 1999).  However, a recent increase in the number of Y. 
pestis outbreaks has led many to consider plague as a reemerging disease (Galimand, et al., 
1997).  The detection of circulating antigen specific for plague is of significant import in 
order to monitor for outbreaks and determine patient treatment.  The circulating antigen, 
F1, is a ‘capsule-like’ surface protein (‘fraction 1’) that has been shown to be an effective 
marker for specific Y. pestis detection (Hsu, et al., 2018). 
 
Dengue virus is a member of the genus flavivirus (Flaviviridae family) and consists of four 
unique serotypes (dengue-1, dengue-2, dengue-3 and dengue-4) (Simmons, Farrar, van 
Vinh Chau, & Wills, 2012).  During the acute phase of the infection cycle by dengue, a 
non-structural protein, NS1, is often found at high concentrations in human serum samples 
(Librarty, et al., 2002) (typically prior to a significant antibody response in primary infec-
tions).  This has become a significant target for the specific detection of dengue infection 
during the early stages of the disease and several commercial assays targeting dengue NS1 
have been developed and evaluated (Pal, et al., 2014).  The discovery and maturation of 
high affinity ligands (antibodies) that target serum NS1 is critical for immunoassay devel-
opment.  
 
An example application of multiplexed kinetic analysis of ligands is shown in Figure 33.  
Here, completely unrelated antigens, Y. pestis F1 and dengue NS1 protein were injected 
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over the same chip at different time points in the assay.  If the analyte-ligand interactions 
are independent of one another, then the kinetic performance for each ligand type may be 
evaluated even if the unrelated analytes were injected simultaneously.  However, we did 
not want to make the assumption that the analyte-ligand binding events were completely 
independent (e.g., non-specific binding), and so each analyte was injected separately over 
the time course of the assay.  During each binding event, the unrelated ligand may also 
serve as an additional negative control for the other ligand.  In this manner, multiple unre-
lated ligands can be evaluated when those ligands are spotted onto the same chip, further 
minimizing assay preparation time and reagent costs. 
 
Of some note, the chip used in this assay was intentionally recycled: that is, this specific 
IRIS chip had been used for testing the limits of detection of the NS1 and F1 antigens in a 
previous experiment (performed the day before).  The chip had been stored in buffer at 
room temperature prior to use in this kinetic assay test.  In this way, we were able to demon-
strate both the independence of binding of the analytes to their respective ligand and also 
begin evaluating the robustness of the IRIS chip (with spotted ligands) itself.   
 
Briefly, before beginning the experiment a 0.1 M glycine (pH 2.5) solution was injected 
over the chip surface for 5 minutes to remove any loosely bound antibody and previously 
bound antigen (see paragraph above).  The chip was then subsequently equilibrated with a 
solution of 1% BSA/PBST.  Buffer was injected over the chip for 5 minutes to establish a 
baseline before a solution of 10 µg/ml F1 (~570 nM, diluted into 1% BSA/PBST) was 
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injected.  The F1 antigen was passed over the chip in re-circulation mode for 15 minutes 
before the buffer (1% BSA/PBST) was injected into the IRIS to observe de-binding (t ~60 
minutes).  A solution containing ~8.192 µg/ml NS1 (~182 nM) and ~8.192 µg/ml of F1 
(~468 nM) was then injected over the chip surface (note: this mixed solution of NS1 and 
F1 was ‘left-over’ from serial titrations of NS1 and F1 during the limit of detection assay).   
 
The key injection points for the assay are indicated in Figure 33.  The raw signal values are 
shown here (not normalized to control spots) in order to visualize any non-specific binding 
that may be occurring at these high concentrations of analyte.  
  
 
 
 
 
 
 
 
Figure 33. The binding of F1 and NS1 are shown in separate steps.  F1 binds specifically 
to the F1 specific ligand.  NS1 binds to two separate unique ligands.  No specific binding 
at the negative control spots are observed, as expected.  F1 antigen (10 µg/ml) is injected 
at (1).  At point (2), buffer only (1% BSA/PBST) is injected into the IRIS system.  The NS1 
and F1 antigen mixture (8.192 µg/ml each) is injected at point (3).  This is followed by 
buffer only at (4).   
 
1 
2 
3 
4 
Y. pestis F1 and dengue NS1 binding in IRIS 
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As can be seen, very minimal non-specific binding at high concentrations of analyte are 
observed.  After the injection and de-binding steps for the F1 antigen, very little additional 
binding is observed for the F1 ligand upon the addition of the ~8.192 µg/ml NS1 + F1 
mixed solution.  No significant binding is observed at either the BSA or mAb negative 
control spots.  As minimal non-specific binding is observed between the F1 and NS1 lig-
ands used in this experiment, it is reasonable to conclude that approximate kinetic and limit 
of detection data may be acquired from experiments that use both analytes simultaneously 
– particularly at lower concentrations than used in the experiment here. 
 
Screening ligands in the presence of analytes from the same disease: Y. pestis F1 and 
LcrV 
An additional exemplary dataset demonstrating the specific reactions of multiple ligands 
to multiple analytes is shown in Figure 34.  In this case, the Y. pestis antigens F1 (described 
previously) and LcrV are tested independently by injecting the analytes at different time 
points over the same chip surface.  Although these antigens are derived from the same 
bacterium, Y. pestis, these analytes are not significantly homologous proteins and we would 
not expect to have overlapping epitopes targeted by the same ligand.    
 
The LcrV is a ‘low-calcium response’ virulence antigen, expressed by a Y. pestis plasmid 
(pCD1) that is also responsible for encoding for several other virulence-associated traits 
(Nilles, Williams, Skrzypek, & Straley, 1997).  The LcrV antigen also serves as a potential 
target for both antibody-based therapeutics and immunoassay design (Sittner, et al., 2018). 
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To evaluate a panel of F1 and LcrV ligands, the chip was first functionalized (epoxysi-
lanized) and spotted with the appropriate negative controls and target specific ligands.  Spot 
sizes were ~300 µm in diameter with ~580 µm pitch.  After spotting and incubating over-
night, the chip was washed and blocked before proceeding with the assay (see the Appendix 
for details).  The IRIS chip surface was equilibrated with 1% BSA/PBST prior to initiating 
the assay.  Images were collected every ~9 seconds and analysis was performed as previ-
ously described in order to obtain the binding curves.   
 
As can be seen in Figure 34, buffer only (1% BSA/PBST) was flowing over the chip surface 
for 10 minutes prior to injecting F1 antigen (3 µg/ml diluted into 1% BSA/PBST) for an 
additional 10 minutes.  Buffer was then injected back through the IRIS system to record 
de-binding of F1 to the various ligands.  Note that additional antibody sandwich steps were 
included as part of this assay: this particular application of IRIS will be discussed in more 
detail in subsequent sections.  We only note the presence of these additional binding steps 
at this time.   
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Figure 34.  After initially flowing buffer only through the flow cell, F1 antigen is injected 
into the chamber.  After binding and de-binding events have been recorded, subsequent 
antibody sandwich steps were performed.  The LcrV antigen was injected into the chamber 
at a later time point and LcrV specific interactions were recorded.  Additional antibody 
sandwiching steps were performed at indicated points which will be discussed in a later 
section.  We also note (*) the impact of a bubble that entered the microfluidic chamber on 
the recorded traces.  Each trace represents an individual ligand type spotted on the IRIS 
chip surface [a legend identifying the ligands is not included here as the density impedes 
legibility]. 
 
Upon closer inspection of Figure 34, we note the two distinct antigen binding events: F1 
binding to F1 specific ligands and LcrV binding to LcrV specific ligands.  Additional no-
tations in Figure 34 indicate re-starting of data acquisition and the instance when a bubble 
flowed through the microfluidic chamber.   
 
Figure 35 shows a more detailed view of the LcrV specific ligands specifically binding to 
the LcrV antigen as the analyte enters the chamber (the time has been reset to 0 in this 
F1 Ag 
LcrV Ag 
Ran Buffer, re-set for LcrV 
* (Bubble) 
F1 and LcrV IRIS binding curves 
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graph).  Binding curves were realigned such that each curve starts at Signal (AU) ≡ 0 at 
time t = 0.  Multiple ligands are binding to the LcrV antigen simultaneously under identical 
experimental conditions.  The obvious kinetic differences are apparent upon visual inspec-
tion of the curves; some ligands reach saturation levels rapidly while others approach equi-
librium levels with a more pronounced sigmoidal curve.  Injection start points and stop 
points are indicated with the red, blue and green vertical lines.  An inherent characteristic 
of the IRIS chip is that all ligands will undergo identical experimental conditions in the 
microfluidic chamber and all start and stop time points will be de facto identical.   
 
Figure 35.  A closer look at the LcrV binding curves indicates distinct binding 
characteristic differences.  1:1 binding fits were performed and results are shown in Table 
6. 
 
As can be seen in Figure 35, 1:1 binding fits were estimated for the LcrV ligands and 
feedback was subsequently provided to the assay developer working on the LcrV specific 
LcrV IRIS binding curves 
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lateral flow immunoassay for potential antibody selections.  Single point values for kon, 
koff, and K𝐷 were generated to provide a relative perspective on the reactivity of each lig-
and with the target analyte; these are provided in Table 6.   
 
Likewise, a more detailed view of the F1 antigen binding to the F1 specific ligands is shown 
in Figure 36.  For simplicity, 1:1 (Langmuir) binding fit models were applied with results 
shown in Table 5.  Feedback was provided to the assay developer working on the F1 spe-
cific lateral flow immunoassay to aid in antibody down selection.  In similar fashion, the 
point values for 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓, and 𝐾𝐷 were generated for the F1 ligands in order to provide 
relative perspective on the reactivity of each ligand; these are provided in Table 5. 
 
Figure 36.  F1 antigen binding to F1 specific antibodies are shown here with 1:1 fit curves 
indicated.  Low off rates are observed for ligands binding to the F1 antigen.  Additional 
discussions regarding sandwiching steps for subsequent antibodies that are injected into 
the microfluidic chamber are found in further sections. 
F1 IRIS binding curves 
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  IRIS KINETIC PARAMETERS 1:1 
FIT 
REAGENT 𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
F1_N1 5.33 𝑥104 < 1 𝑥10−7 
F1_N2 1.82 𝑥105 < 1 𝑥10−7 
F1_N3 9.58 𝑥104 < 1 𝑥10−7 
F1_N4 7.32 𝑥104 < 1 𝑥10−7 
F1_N5 1.64 𝑥105 1.73 𝑥10−5 
Table 5.  The binding characteristics observed for F1 antigen binding to multiple ligands 
spotted onto the chip surface.  Most of these high-affinity ligands demonstrated 𝑘𝑜𝑓𝑓 rates 
below readily quantifiable limits in the time period recorded ( < 1 𝑥10−7𝑠−1). 
 
 
 
 
  IRIS KINETIC PARAMETERS 1:1 
FIT 
REAGENT 𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
LCRV_L1 1.60 𝑥105 1.87 𝑥10−6 
LCRV_L2 1.71 𝑥105 1.13 𝑥10−5 
LCRV_L3_F2 1.21 𝑥105 7.43 𝑥10−5 
LCRV_L3_5I 1.21 𝑥105 6.62 𝑥10−5 
LCRV_L3_35 1.60 𝑥105 6.21𝑥10−5 
LCRV_L4 4.42 𝑥105 4.42 𝑥10−5 
LCRV_L5 1.60 𝑥105 1.87 𝑥10−6 
LCRV_L6 2.29 𝑥105 < 1 𝑥10−7 
LCRV_L7 4.17 𝑥105 1.25 𝑥10−6 
Table 6. The binding characteristics observed for the LcrV antigen binding to multiple 
ligands spotted onto the chip surface are shown here.   
 
Kinetic parameters for F1 ligands 
Kinetic parameters for LcrV ligands 
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While the point data kinetic information provides some significant utility for assay design, 
a more complete picture may yet be formed once the complementary activity of potential 
antibody pairs are better understood.  This is discussed in further detail in the section: 
Sandwiching multiple ligands to screen for appropriate binding pairs:  Y. pestis. 
 
Screening multiple antibodies for reactivity against multiple analytes: dengue NS1 
As discussed in a previous section, dengue is a member of the flavivirus genus with four 
unique serotypes: dengue-1, dengue-2, dengue-3 and dengue-4.  Infection with this mos-
quito-borne, single stranded RNA (positive sense) virus is typically self-limiting, but 
causes significant global health and economic burdens with approximately 50 million in-
dividuals infected annually (Simmons, Farrar, van Vinh Chau, & Wills, 2012).  Prior in-
fection by one serotype does not confer immunity to the other serotypes and may, in fact, 
be linked to further complications of the disease such as dengue hemorrhagic fever (Rigau-
Pérez, et al., 1998).  The non-structural protein 1 (NS1) has been effectively used for the 
specific early detection of dengue infection.  Circulating serum level concentrations of 
dengue NS1 may range from ng/ml → µg/ml during the first few days of dengue infection 
(Librarty, et al., 2002) (Pal, et al., 2014). 
 
For the development of immunoassays targeting dengue NS1, it is important to develop 
ligands that recognize all four serotypes with high affinity.  Alternatively, serotype specific 
reagents may be developed to use for classifying dengue infection by serotype (Ding, et 
al., 2011).  Additional requirements to limit cross-reactivity with related flavivirus NS1 
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proteins may also be required as part of the development cycle of the immunoassay.  It is 
worth emphasizing that many other flaviviruses – including Zika virus – express potentially 
cross-reactive NS1 proteins and the potential for homologous epitopes should be taken into 
account during assay design.     
 
One of the earlier IRIS experiments performed at InBios International, Inc evaluated a se-
ries of monoclonal antibodies targeting dengue NS1.  Antibodies were spotted in replicate 
spots with an approximate 100 µm diameter onto an epoxysilanized IRIS chip.  Test anti-
bodies and controls were spotted in replicates of n = 10 in a vertical format.  After washing 
and blocking, the chip was attached to a pressure sensitive adhesive (PSA) flexible co-
verslip.  (This coverslip is made of a flexible material that was found to shift (‘flex’) during 
data acquisition.)  Data points (image slices) were collected every ~6 seconds to record 
binding events. 
 
Recombinant dengue NS1 (source: Native Antigen Company) was injected into the flow 
cell at the points indicated in Figure 37.  Dengue NS1 from dengue-1, dengue-2, dengue-
3 and dengue-4 was injected into the microfluidic chamber.  Antigens were diluted to 10 
µg/ml (~220 nM) into a 1% BSA/PBST buffer.  After the injection, binding and de-bind-
ing steps were recorded, the bound antigen was eluted from the antibodies by use of a 0.1 
M glycine solution (pH 2.5) before subsequently running buffer and the next NS1 anti-
gen.   
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Figure 37.  Dengue NS1 antigens (representing dengue-1, dengue-2, dengue-3 and dengue-
4) was injected into the IRIS microfluidic chamber at the indicated time points.  Binding 
and de-binding curves were recorded for each antibody.  Antigens were eluted from the 
antibodies between runs as noted in the text. 
 
Initial observations indicated a ‘wavy’ pattern that was observed in the collected binding 
curves with visible oscillatory patterns in the image sequence.  This seems most likely due 
to the use of a flexible PSA coverslip during data acquisition.  Nonetheless, informative 
data was readily obtained to indicate antibody specific and approximations of the relative 
kinetic data for each ligand.   
 
The behavior of a few exemplary antibodies is shown in Figure 38.  It becomes readily 
apparent that NS1_D8 has dominant reactivity to dengue-1 NS1 protein, whereas NS1_D3 
has dominant reactivity with the dengue-2 NS1 protein.  NS1_D7 demonstrated binding to 
all four serotypes, but with some preference to dengue-1 and dengue-3 with a significantly 
Dengue-1 Dengue-2 Dengue-3 Dengue-4 
Dengue NS1 binding (serotype specificity) 
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greater 𝑘𝑜𝑓𝑓 rate than the other two monoclonal antibodies.  Even qualitative data such as 
this may help for the creation of either broadly reactive or serotype specific NS1 immuno-
assays. 
 
Figure 38.  Example antibodies with unique binding characteristics for dengue NS1 are 
shown here.  As can be seen, antibodies may be broadly reactive or serotype dominant.  
Rapid determination of the serotype specificity for each antibody may aid in the creation 
of serotype specific immunoassays. 
 
Using the IRIS in this manner, many antibodies can be rapidly characterized for binding 
affinity and specificity with dengue NS1 antigens using limited antibody and analyte vol-
umes in a single experiment.  For additional reference, slices from the generated sequences 
of ‘difference’ images are shown in Figure 39. 
  
Example antibodies demonstrating serotype 
specificity for dengue NS1 
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Figure 39.  Sample image slices from the sequence of ‘difference images’ are shown here.  
The images are generated by subtracting the image collected from the very first image in 
the image stack from all subsequent images.  (a) No binding is observed at the spots prior 
to injecting NS1 antigens. (b) Specific dengue-1 NS1 binding.  (c) Specific dengue-2 NS1 
binding. (d) Specific dengue-3 NS1 binding. (e) Specific dengue-4 NS1 binding.  Spots were 
placed onto the IRIS chip in vertical replicates of n = 10.  Columns of dark spots may be 
indicative of poorly bound antibody (eluted after exposure to 0.1 M glycine). 
  
(a) 
(b) (c) 
(d) (e) 
Image slices representing dengue NS1 binding 
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Sandwiching multiple ligands to screen for appropriate binding pairs:  B. anthracis 
The unique utility of the IRIS system for screening and evaluating multiple binding part-
ners becomes apparent as the number of ligands of interest is increased.  A ‘real-world’ 
problem arose at InBios International, Inc with the need to rapidly screen multiple ligands 
to select for (1) high affinity binders (2) binders that react with epitopes present on different 
antigens and (3) appropriate ligand binding pairs.  Dozens of ligands with unknown binding 
characteristics needed to be rapidly evaluated to choose the best possible candidates for 
use in a lateral flow immunoassay.  Ligands needed to be selected that could bind to both 
free lethal factor (LF) and lethal toxin (LTx).  The ligands were required to have suffi-
ciently acceptable affinity constants for use in lateral flow immunoassay development.  Ad-
ditionally, it was informative and necessary to select for ligands that would act as appro-
priate binding pairs with ligands that were previously considered the primary candidates 
for this assay development.   
 
A preliminary assay was performed to determine ligands that had the highest apparent 𝑘𝑜𝑛 
and 𝑘𝑜𝑓𝑓 rates targeting LF.  It was necessary not only to determine the best binding pa-
rameters, but also to determine those ligands which pair well with a complementary anti-
body (‘sandwich’).  This ability to sandwich analyte between two antibodies which target 
distinct epitopes is foundational to antigen detection immunoassays.   
 
Ligands targeting LF were spotted (~100 µm diameter) in replicates of n = 10 onto an 
epoxysilanized IRIS chip.  An example image of a spotted chip is shown Figure 40, where 
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common problems of misprints (missing spots) and varying spot morphology (due to ligand 
buffer differences) are readily apparent.  The quality of the spotter and techniques used for 
spotting have a direct impact on the quality of data that is subsequently recorded.  The use 
of a more advance, non-contact spotter may significantly improve future IRIS tests. 
 
 
 
 
 
 
 
 
 
Figure 40.  The IRIS chip with a series of ligands targeting LF are spotted here.  Note that 
this image was acquired immediately after spotting the chip surface.  Ligands were spotted 
in replicates of n = 10.  It becomes immediately apparent how the quality of the spot 
(morphology, missing spots, etc.) may directly impact the assay performance. 
 
After spotting, blocking and washing (see Appendix for protocol), the chip was loaded into 
the IRIS system and equilibrated with buffer (1% BSA/PBST).  After equilibration, the 
assay was performed as follows:   
(1) Analyte (LF antigen, 10 µg/ml) was injected into the microfluidic chamber for 20 
minutes. 
(2) Buffer was then pushed through the chamber for ~60 minutes to record de-binding. 
Post spotting image indicating spot lo-
cations and morphology of LF ligands 
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(3) Potentially sandwiching antibodies were sequentially injected into the chamber at 
concentrations of 10 µg/ml for ~20 minutes at each step. 
(4) Antigen-antibody complexes were eluted from the covalently linked ligands using 
0.1M glycine, pH 2.5, for ~10 minutes. 
(5) The chip was subsequently equilibrated with buffer (1% BSA/PBST). 
(6) LF antigen (10 µg/ml) was again injected into the chamber for 20 minutes and 
binding was recorded. 
(7) Buffer was pushed through the chamber for ~60 minutes to record de-biding events. 
(8) A different set of potentially sandwiching antibodies were sequentially injected into 
the chamber at concentrations of 10 µg/ml for ~20 minutes at each step. 
 
The recorded mean binding curves for each ligand is shown in Figure 41.  The primary and 
secondary injections of LF lead to immediate binding events.  Step-like binding patterns 
are observed with the addition of each subsequent antibody binding pair, assuming epitope 
availability is not constrained. 
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Figure 41.  The separate injections of analyte and potentially sandwiching ligands are 
indicated here.  The red arrows indicate the injection of LF antigen which is followed by a 
buffer only step to record the dissociation phase.  Each (*) is indicative of the injection of 
an additional potentially sandwiching ligand.  Legend is not shown for clarity, but negative 
control spots show no or minimal binding for each injected analyte. 
 
In Figure 42, we more closely examine two exemplary binding curves to note the specific 
information gained regarding each ligand.  Additionally, the BSA and mouse IgG 
(NS1_D9) negative control spots are shown.  The initial kinetic 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates may be 
calculated during the primary binding and dissociation phases.  The subsequent sandwich-
ing of additional ligands displays unique behavior.  As seen in Figure 42, upon addition of 
one complementary binding antibody, continued mass accumulation is observed for one 
ligand while active de-binding is observed for the other. These observations may be indic-
ative that the ligand presenting the LF antigen (to the binding pair that is being injected 
into the solution) may present the epitope favorably or unfavorably and, additionally, may 
compete with the complementary antibody itself.    In another binding pair event, the curves 
* 
* 
* * * 
* 
* 
* 
Evaluating several LF ligands and potential binding pairs 
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of the complementary binding are distinctly different, indicating a faster on rate for one 
ligand pair over the other.   
 
 
 
 
 
 
 
 
Figure 42.  The unique behavior of each spotted ligand is exemplified in the binding curves 
shown here.  Red arrows indicate the injection of LF antigen while the (*) indicates the 
elution and regeneration point.  The kinetic on and off rates may be estimated with the 
binding and de-binding phases shown at (a).  The favorability (observed on-rate and 
sigmoidal curve) of sandwiching a subsequent antibody that is injected into the solution 
may vary from one ligand to the next, as shown in (b).  Direct competition for available 
epitopes may cause de-binding to occur, as seen in (c).  Subsequent antibody pairings 
shown at (d) indicate that one ligand (JMO-G1) binds favorably with the injected antibody 
whereas the other ligand (LF_19) does not. 
 
Of note, the relative 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates were estimated for both the primary LF binding 
stage and with the additional complementary binding pairs (𝑘𝑜𝑛 only).  The ligands that 
demonstrated the best sandwiching characteristics in this IRIS testing lined up very closely 
to the selected membrane – conjugate pairs that were selected by another investigator man-
ually and individually testing each potential pair in ELISA and lateral flow immunoassay 
(data not shown). 
(a) 
(b) 
(c) 
(d) 
* 
Selected LF ligands demonstrating unique binding characteristics 
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Additional investigations were subsequently performed to evaluate the binding kinetics for 
a variety of ligands using LF antigen and LTx (lethal factor toxin) as the analyte.  LTx is 
formed from the complex of LF with oligomeric forms of protective antigen.  The PA 
heptamerizes to form a ring-like structure and it has been shown the LF binds only to mul-
timers of PA (dimers or greater).  The heptameric form of PA may bind up to three different 
LF proteins  This LF-PA complex is a key component of the toxicity of anthrax infection 
and is significant for the endocytosis of LF through the cell membrane and into the cytosol 
(Mogridge, Cunningham, Lacy, Mourez, & Collier, 2002) (Lacy, et al., 2005).   
 
The LTx complex may be quite large, with varied molecular weights given the multimeri-
zation of the PA (~63 kDa each) and the fact that one to three LF proteins may bind to the 
multimeric form of PA implies a heterogenous molecular weight with varying epitope 
availability.  From the diagnostic perspective, it is additionally important to keep in mind 
that as the LTx complex is formed, LF epitope availability may be reduced or unavailable 
for some of the ligands.  In a human anthrax infection, both LF and LTx may be present 
and selecting for ligands that may react with both is of some import.   
 
It was desirable to evaluate the relative affinities of each ligand to LF and LTx, as well as 
select potential binding partners, in a single IRIS assay.  IRIS chips were functionalized 
with epoxysilane and subsequently spotted with replicates (n=3) of each ligand.  After 
washing and blocking, the chip was loaded into the IRIS system as described previously 
(Needham, Lortlar Ünlü, Yurdakul, & Ünlü, 2019).  LTx was formed by complexing free 
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LF with PA at a mass ratio of 5:1 (PA:LF, 15 µg/ml of PA to 3 µg/ml LF) diluted into 1% 
BSA/PBST.  This mass ratio was selected as it tends to form a mostly complete complex 
of PA to LF (Singh, Klimpel, Goel, Swain, & Leppla, 1999).  Buffer (1% BSA/PBST) was 
first injected over the chip to establish equilibrium levels prior to injecting lethal toxin 
(LTx) for 20 minutes.  Buffer was then injected over the chip surface to establish the dis-
sociation kinetics for each ligand.  Four additional ‘sandwich’ ligands were then sequen-
tially injected over the surface at 10 µg/ml concentrations.  Each complementary ligand 
was injected for approximately 20 minutes prior to the addition of the next ligand.  The 
complexes were then eluted using 0.1M glycine, pH 2.5, injected over the surface for 5 
minutes before again equilibrating the surface with 1% BSA/PBST.  Lethal factor (LF, 10 
µg/ml) was subsequently injected into the flow cell to evaluate the binding kinetics for free 
LF and a similar procedure was followed to run buffer and sandwiching ligands (n=2) to 
find appropriate binding pairs.   
 
As can be seen in Figure 43, a significant amount of data is generated with this experi-
mental setup.  The binding affinities for each ligand can be estimated and – perhaps more 
importantly – the relative 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates are determined side-by-side for each ligand 
under identical experimental conditions.  Critical information for each ligand can be deter-
mined such as whether or not a ligand binds to both LF and LTx, whether the ligand has 
an appropriate binding pair with key ligands under investigation, etc.   
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Figure 43.  The complete set of binding curves obtained for LTx and LF antigen binding 
and complementary binding pairs are shown here.  Example image slices at representative 
time points are indicated.  While many ligands bind both LTx and LF, there are several that 
exhibited different binding behavior and some which bound only to LF.  Additional 
information from complementary ligand binding pairs helped select relevant antibody 
pairs for use in immunoassays. 
 
In order to better understand the significance and utility of data that are quickly generated 
from a single experiment as shown in Figure 43, we focus on a more readily understood 
subset of data shown in Figure 44.  In addition, negative control BSA and mouse IgG spots 
LF Toxin (LTx) LF Antigen 
LF and PA ligands binding to LTx and LF analytes 
with complementary ligands 
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are included for reference and we note that both the BSA and mouse IgG negative control 
antibody (NS1_D6) maintain a low baseline signal and demonstrate no significant binding 
throughout the experiment.  In this figure, we can clearly see the specific binding of one 
ligand (LF_16) to both LTx and LF.  However, two other LF specific ligands (LF_8 and 
LF_30) are, in fact, LF specific.  That is, the LTx complex that is formed by LF and PA 
apparently hides the epitopes that LF_8 and LF_30 specifically recognize; this would be 
indicative that we should not pursue LF_8 and LF_30 for inclusion in a potential immuno-
assay as they may not recognize the LF as it is presented in a potential human infection.   
 
 
 
 
 
 
 
 
 
Figure 44.  The binding of LTx and LF to select LF ligands is shown here.  As can be seen, 
LF_8 and LF_30 bind only to LF antigen and do not seem to bind to the LTx complex.  
LF_16 binds significantly to both the LF and the LTx complex.  Negative control spots 
showed no significant binding throughout the experiment. Complementary antibodies are 
also injected at various time points and are informative for the selection in potential 
immunoassays.  
 
LF Toxin 
(LTx)
LF 
Antigen
Selected LF ligands: LTx vs. LF preferences 
90 
 
 
Sandwiching multiple ligands to screen for appropriate binding pairs:  Y. pestis 
As previously noted, the testing performed with LcrV and F1 antigens for Y. pestis not only 
provided multiplexed estimations of the kinetic parameters, 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓, but additional 
antibody ‘sandwich’ information was determined in the same experiment by the subsequent 
addition of potentially complementary antibodies into the system.  For convenience, Figure 
34 is reproduced here and additional notations indicating the identity of the complementary 
antibodies that are injected into the system are included. 
 
 
 
 
 
 
 
 
 
 
Figure 45.  The F1 and LcrV ligand – antigen binding curves are reproduced here with 
additional notations indicating the injection of unique ligands and their identities.   
 
A great deal of immediate, qualitative information is gathered upon reviewing the observed 
binding once complementary antibodies are injected into the microfluidic chamber.  A 
summary qualitative binding table for each antibody is provided in Table 7 and Table 8.   
F1 Ag 
F1_N1 
F1_N2 
LcrV Ag 
LcrV_L1 
LcrV_L2 
Ran Buffer, re-set for LcrV 
* (Bubble) 
F1 and LcrV IRIS binding curves 
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Reagent: F1_N1 
mAb 
F1_N2 
mAb 
F1_N3 ++ ++ 
F1_N4 ++ ++ 
F1_N1 + ++ 
F1_N2 + ++ 
F1_N5 + ++ 
Table 7.  The qualitative complementary binding of F1_N1 and F1_N2 to five potential 
ligand candidates are indicated here.  The various ligand reagents were spotted onto the 
IRIS chips surface, F1 antigen was injected for initial analyte binding and F1_N1 and 
F1_N2 antibodies were sequentially injected to monitor for an effective complementary 
pair.   
 
 
Reagent: LcrV_L1 
mAb 
LcrV_L2 
mAb 
LcrV_L2 ++ - 
LcrV_L3_F2 ++ - 
LcrV_L3_5I ++ - 
LcrV_L3_35 ++ - 
LcrV_L4 ++ ++ 
LcrV_L5 - ++ 
LcrV_L6 - ++ 
LcrV_L7 ++ - 
Table 8.  The qualitative complementary binding of LcrV antibodies, LcrV_L1 and 
LcrV_L2, to several potential ligand candidates is indicated here.  The multiple ligands 
were spotted onto the IRIS chips surface, LcrV analyte was injected into the chamber and 
this was followed by the sequential injection of LcrV_L1 and LcrV_L2.  It is noteworthy 
that almost all antibodies sandwiched well with either LcrV_L1 or LcrV_L2, but not both.  
Only LcrV_L4 sandwiched effectively with both LcrV_L1 and LcrV_L2.   
 
For the sake of clarity and to point out some illustrative features, we show a subset of the 
F1 binding assay in Figure 46 and a subset of the LcrV binding assay in Figure 47.  The F1 
binding assay is illustrative of the antibody F1_N2 (the highest affinity F1 antibody, see 
Qualitative performance of F1 binding pairs 
Qualitative performance of LcrV binding pairs 
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Table 5) and we note significantly that the F1_N2 antibody binds itself.  The apparent 
relative 𝑘𝑜𝑛 rate of this complementary binding step also seems to be the greatest amongst 
all the spotted LF ligands (see Figure 45).  
 
 
Figure 46.  A subset of the F1 binding assay is shown here.  Negative controls (BSA and 
an unrelated mouse IgG antibody) demonstrate no specific binding.  F1_N2 antibody binds 
to the F1 antigen with an apparently high affinity (see Table 5), sandwiches with F1_N1 
and, interestingly, sandwiches rapidly and effectively with itself. 
 
The LcrV binding assay is exemplified by closely evaluating the spotted ligands, LcrV_L1 
and LcrV_L2.  We note the results when LcrV antigen is first injected followed by the 
sequential injections of LcrV_L1 and LcrV_L2.  It is apparent that neither LcrV_L1 nor 
LcrV_L2 are self-complementary, however they do pair with one another (i.e., we can form 
an LcrV_L1 ↔ LcrV ↔ LcrV_L2 immunoassay complex).   
F1 Ag 
F1_N1 
F1_N2 
F1_N2 mAb binds to F1 antigen and sandwiches F1_N2 
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Figure 47.  It is apparent that both LcrV_L1 and LcrV_L2 bind specifically to the LcrV 
antigen and that LcrV_L1 forms a complementary binding pair with LcrV_L2.  Red arrows 
indicate the injection time point for each sequentially added analyte.  A bubble (*) that 
entered the chamber is also noted.   
 
The information collected here for F1 and LcrV binding was provided to the technician 
developing assays targeting F1 and LcrV.  Of note, the technician developing the F1 assay 
screened each of the possible binding pairs for use in a lateral flow immunoassay and the 
best candidate for F1 detection was indeed the F1_N2 ↔ F1_N2 binding pair.  An example 
lateral flow assay from this screening test is shown in Figure 48.  Here, F1_N2 antibody is 
striped onto a nitrocellulose membrane and F1_N2 antibody is also conjugated to gold 
nanoparticles using standard lateral flow immunoassay (LFI) techniques.  Without 
optimization, initial screening of the F1_N2 binding pair showed sensitivity down to ~5-
10 ng/ml F1 antigen in the LFI format.   
  
LcrV Ag 
LcrV_L1 
LcrV_L2 
(Bubble) * 
LcrV binding assay: LcrV_L1 and LcrV_L2 
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Figure 48.  The F1_N2 binding pair was found to be the most sensitive of the potential 
ligand pairs evaluated in the lateral flow assay.  During screening (non-optimized assay), 
signal for F1 antigen was observed down to ~5-10 ng/ml.   
 
From both of these examples – anthrax LF ligand binding pairs (targeting LF and LTx) and 
Y. pestis binding pairs (targeting both F1 and LcrV) – we see that a wealth of information 
may be rapidly generated to steer immunoassay development.  In addition to estimating 
𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates directly, we may additionally determine appropriate binding partners 
and also note the relative affinity of these binding partners during the sandwich step.  Mul-
tiple antigens and potentially epitope constrained analytes may be evaluated sequentially.  
As each analyte is screened against the array of ligands spotted onto the chip surface, we 
may rapidly rank potentially ideal immunoassay binding partners in a limited time frame.  
 
Control 
Test line 
Example lateral flow immunoassay using the 
F1_N2 ↔ F1_N2 binding pair  
95 
 
 
Conclusion: 
Here, we have performed a number of multiplexed kinetic binding studies, evaluating both 
the qualitative and quantitative performance of a variety of ligands from several disease 
states.  We have demonstrated that multiple different antigens from unrelated diseases may 
be sequentially injected into the IRIS chip with minimal cross-reactivity (see Figure 33).  
Additionally, we have shown that antigens from the same disease (however, not homolo-
gous) may also be sequentially injected and multiplexed ligand binding activity may be 
observed (see, for reference, Figure 34).  Furthermore, NS1 antigens representing the four 
different dengue serotypes were sequentially injected in order to measure the binding char-
acteristics of multiple dengue monoclonal antibodies simultaneously. 
 
The additional utility of determining the complementary binding activity of these multi-
plexed ligands adds a significant amount of information to an already dense dataset (for 
reference, see Figure 43).  With a single assay, we may determine the kinetic binding char-
acteristics for hundreds of ligands targeting multiple analytes with the additional benefit of 
evaluating several potential complementary antibodies immediately with the bound ligand 
– analyte complex.  This key ability may drastically improve the efficiency of immunoas-
say development and more quickly steer reagent selection and assay structure.  
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Chapter 8 Limits of detection and improvements to IRIS sensitivity 
To evaluate the sensitivity (analytical limits of detection), two different analytes (dengue 
NS1 and Y. pestis F1) were tested using high affinity antibodies as capture ligands on the 
chip surface.  These analytes represent two different disease types and were also chosen to 
represent a breadth of molecular weights (NS1 is ~45 kDa and F1 is ~17.5 kDa).  The 
comparison of the relative analytical sensitivity of the IRIS system to other label-free meth-
odologies will directly speak of the ultimate utility that this multiplexed platform may have.  
To that end, we will compare the data obtained with the current IRIS system and method-
ology to previous data sets (Ahn, Performance Improvement of Label-Free Biosensors and 
their Applications in DNA and Protein Microarrays, 2013) and also to published limits of 
detection obtained with various SPR sensing modalities (Homola, 2008).   
 
Evaluating the limit of detection with dengue NS1 and Y. pestis F1: 
Functionalized IRIS chips were spotted with NS1 and F1 ligands in replicate and binding 
curves ultimately represent the average of n = 3 spots (~300 µm in diameter).   The chip 
surface was equilibrated with buffer (1% BSA/PBST) for ~1 hour prior to injecting in-
creasing concentrations of NS1 and F1 antigens.  Negative controls included BSA spots 
and an unrelated mouse IgG1 antibody.   
 
Analytes were simultaneously injected over the chips surface at increasing 4-fold 
concentrations, starting from 0.5 ng/ml to 8,192 ng/ml.  These analytes demonstrated no or 
limited cross-reactivity with the unrelated ligand – see Figure 33 for reference.  The analyte 
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continuously flowed over the surface (recirculation mode) for 45 minutes before the next 
concentration step was injected.  The raw binding curves – the signal observed as a function 
of time – are shown in Figure 49.  Individual ‘bumps’ may be observed in Figure 49 which 
indicate the injection of increasing concentrations of the respective analyte.  Negative 
control spots are shown and non-specific binding is not observed until high concentrations 
of the analytes are reached (4-8 µg/ml, particularly at the mouse IgG negative control).  We 
also note that even though the individual incubation times with each concentration of 
analyte was 45 minutes, equilibrium levels were often not reached, particularly at lower 
concentrations of analyte.  Potential further improvements to the estimated limits of 
detection may be obtained as the binding approaches equilibrium. 
 
 
 
 
 
 
 
 
 
Figure 49.  The raw signal values obtained as a function of time are shown for each of the 
ligands of interest along with negative controls.  Binding curves represent the average 
signal from n = 3 replicate spots.   
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To produce a titration curve from the data collected in Figure 49, a single data point (with 
error) for each injected concentration must be determined.  This was titration curve was 
generated by taking the mean value and standard deviation of the last 5 minutes of recorded 
data for each injected concentration level.  Titration curves for each ligand and control are 
normalized to the 0 ng/ml condition.  The results of this analysis are shown in Figure 50 
and Figure 51.  Error bars represent ± 1 standard deviation (𝑆𝐷) at each concentration (over 
the 5-minute period).  The analyte is considered detectable when the signal is ≥ 𝑚𝑒𝑎𝑛 +
( 3 𝑥 𝑆𝐷) of the negative control ligands. 
 
 
 
 
 
 
 
Figure 50.  The binding curves obtained as the concentrations of NS1 and F1 antigens 
are increased in 4-fold steps.  Each data point represents the average and standard 
deviation for the last 5 minutes of collected data prior to injecting the next highest 
concentration (see Figure 49 for reference).   
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Figure 51.  Closer inspection of the F1 and NS1 titration curves indicate that both analytes 
are detectable at ~2 ng/ml (greater than three standard deviations above the control 
ligands).  The lowest injected concentration – 0.5 ng/ml – was not significantly above the 
background control spots after 45 minutes.  Once 8 ng/ml of the F1 and NS1 proteins were 
injected into the microfluidic chamber, direct binding events became clear.  
 
Comparisons to previously obtained limits of detection: 
For reference, previously obtained limits of detection and real-time binding curves for a 
similarly sized protein, interleukin-6 (IL-6, MW ~21kDa), using a previous IRIS iteration 
are provided in Figure 52.  The improvements obtained with the most recent IRIS iteration 
and updated assay techniques become apparent when comparing Figure 49, Figure 50, and 
Figure 51 to Figure 52.  It is noteworthy that the LoD values obtained in Figure 52 were 
improved by the introduction of a ‘mass-tagging’ method and a significant improvement in 
the assay sensitivity is obtained when a complementary antibody is introduced into the 
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chamber.  The limit of detection for the direct detection of IL-6 was reported at 19 ng/ml.  
Using the mass-tagging method, the limit of detection improved to 2.7 ng/ml (Ahn, 
Freedman, Massari, Cabodi, & Ünlü, 2013).  In the assay performed for the LoD testing 
of NS1 and F1 proteins, no ‘mass-tagging’ methodology was employed and we are 
observing the sensitivity of the direct binding event. 
 
As can be seen in Table 9, the direct detection of NS1 and F1 proteins demonstrated the 
improved the direct detection of analyte over previous IRIS iterations by a factor of ~10-
fold with limits of detection approaching or exceeding the previous ‘mass-tagging’ meth-
ods.  The limit of detection is here defined as the concentration point at which the signal is 
greater than the mean plus three standard deviations of the negative control ligands.  The 
observed limits of detection for both NS1 and F1 antigens was approximately ~2 ng/ml in 
a 1% BSA/PBST buffer and are clearly distinguishable from control ligand reactivity at 8 
ng/ml.  It is also noteworthy to compare binding data obtained in Figure 52(a) to binding 
data obtained in Figure 33; similar MW proteins are first shown binding via a direct detec-
tion method and the significant improvements to assay noise are apparent.  We also note 
the timescale of the binding events when comparing Figure 52(a) to Figure 33; the IL-6 
direct binding event occurs over a ~60 minute period whereas the F1 binding occurs over 
a ~10 minute interval, further indicating the improvements to the fluidic handling and assay 
design are significant.  
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Figure 52.  Previously published (Ahn, Performance Improvement of Label-Free 
Biosensors and their Applications in DNA and Protein Microarrays, 2013) binding curves 
for IL-6 and anti-IL-6 are shown here.  IL-6 and a complementary anti-IL-6 antibody were 
injected at 1 µg/ml concentrations in (a).  Titrations of IL-6 were evaluated in both direct 
and with a ‘mass-tagging’ approach in (b).   Reprinted (adapted) with permission from 
(Ahn, Performance Improvement of Label-Free Biosensors and their Applications in DNA 
and Protein Microarrays, 2013).  Copyright 2013, American Chemical Society.  
 
Previously published IRIS binding curves 
 (IL-6 binding)  
(a) 
(b) 
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Target Analyte Approximate 
MW 
Reported 
LoD 
Detection Method 
IL-6 21 kDa 2.7 ng/ml Mass-tagging, 2013 IRISa 
IL-6 21 kDa 19 ng/ml Direct detection, 2013 IRISa 
F1 17.5 kDa 2 ng/ml Direct detection, 2018 IRIS 
NS1 45 kDa 2 ng/ml Direct detection, 2018 IRIS 
a (Ahn, Freedman, Massari, Cabodi, & Ünlü, 2013) 
Table 9.  The previously reported limits of detection with IL-6 are compared to the direct 
detection methods obtained with the most recent IRIS iteration and assay methodology. 
 
 
Comparison of the limit of detection to SPR instrumentation 
It is also important to understand how the sensitivity (analytical reactivity) of the IRIS 
platform compares with more traditional label-free detection methodologies and, in partic-
ular, SPR.  A literature review found a wide variety of reported limits of detection which 
vary upon the instrument used, the analyte-ligand pair, the buffer system used (e.g., serum), 
etc.  The limits of detection for SPR based instrumentation was well summarized in 
(Homola, 2008), and sensitivities varied depending on the analyte, equipment and detection 
methodology.  Using the Biacore Q for the direct detection of protein ranged from 0.7 
ng/ml for folate-binding protein, 1.1 ng/ml for lactoferrin, 16.8 ng/ml for IgG and 75 ng/ml 
for lactoperoxidase.   The staphylococcal enterotoxin, SEB, was reported to have a limit of 
detection of 1 ng/ml with the Biacore X, 10 ng/ml with a fiber optic based SPR system and 
5.6 ng/ml with a Spreeta system – all using the direct detection method.  The Biacore 2000 
provided a limit of detection of 10 ng/ml for the direct detection of prostate specific antigen 
Improvements to IRIS limit of detection 
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(PSA) diluted into buffer.  See (Homola, 2008), Tables 1 and 2, for additional reference.   
 
Given this, the analytical reactivity of the IRIS system seems to perform at a similar level 
of sensitivity when using three spots (~300 µm in diameter) for each ligand.  Of course, 
the noise floor and corresponding limit of detection may depend upon the area of the active 
spot; the greater the area, the more pixels are associated with each ligand and the noise 
floor of the assay may correspondingly improve.  This may be indicative that the measure-
ments obtained here are shot-noise limited with improvements to the noise floor propor-
tional to the square root of the area (i.e., the square root of the number of photons collected 
per unit time).  However, the flexibility of the IRIS system allows the end user to com-
pletely control the number and size of the ligands that are spotted and, therefore, signifi-
cantly control the noise floor of the assay, depending upon the specific assay requirements.  
 
Conclusion: 
The IRIS system has demonstrated significantly improved limits of detection with the latest 
iteration in tandem with improved assay methodology.  The current LoD for two different 
analytes now approaches ~2 ng/ml for the direct detection of circulating protein using the 
average of n = 3 spots for the generated signal.  This has improved the previously reported 
limits of detection of the IRIS instrument by ~10-fold and is comparable to current SPR 
sensitivity limits.  
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Chapter 9 Additional utilities of the IRIS platform 
In addition to providing multiplexed determination of kinetic information and evaluating 
binding pairs for complementary activity, the IRIS platform may be used for a variety of 
other applications.  To that end, we have evaluated the IRIS system for potential additional 
utilities, including (1) Screening unpurified antibodies present in tissue culture supernatant 
(2) Monitoring genetically modified reagents to qualify reactivity (3) Confirmation of the 
reactivity of subcloned antibodies and (4) Monitoring self-assembly (oligomerization) of 
proteins.   
 
Screening unpurified antibody in culture supernatant 
Additional applications of IRIS technology may include screening monoclonal antibody 
(mAb) supernatant directly.  In this case, two potential formats are available.  The simplest 
format includes spotting potential antigens or epitope targets onto the chip surface.  A di-
lution of the unpurified supernatant may then be run over the chip surface to establish the 
specificity of binding (“yes” / “no”) to any given target on the chip surface.  However, this 
method limits the screening of mAb supernatants to one at any given time (i.e., sequential 
passes of unique supernatants over the chip surface).  If the concentration of the antibody 
in the cell culture supernatant is known, then the kinetic parameters may be estimated.  This 
format is less amenable to the situation that is typically found during assay development 
where a given scenario might include a limited number of target analytes (e.g., antigens) 
and a large library of potential unpurified antibodies to screen.  It should also be noted that 
the potential unfolding of the target antigens onto the chip surface may deleteriously impact 
the functionality or activity of the epitope as it is presented to any ligand that is in solution.   
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A more useful format would include the parallel screening of multiple unpurified mAb 
supernatants targeting a single analyte.  To achieve this possibility, we spotted (~100µm 
diameter) replicates of goat-anti mouse IgG (H+L) antibody onto the IRIS chip surface.  
After spotting, incubating, washing and drying, dilutions of mouse monoclonal antibodies 
(diluted into cell culture supernatant) were spotted (~300 µm diameter) directly on top of 
the previous capture reagents.  In this manner, unpurified mouse antibody may be harvested 
from the solution and enriched at the chip surface to provide a significant signal for screen-
ing.  Mouse mAb was diluted from 1 mg/ml → 1 µg/ml in order to cover a concentration 
range that may be typically found in antibody supernatant solutions.  An illustration for 
this enrichment approach is shown in Figure 53.  
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Figure 53.  The attempted enrichment process to capture antibodies from cell culture 
supernatant is illustrated here.  In (a), anti-mouse IgG antibody is first spotted onto the 
chip using ~100 µm diameter spots.  The chip is then washed to remove unbound anti-
mouse IgG and dried in (b).  Subsequent spots of culture supernatant containing mouse 
IgG are the spotted on top of the anti-mouse IgG spots in larger volumes (spot sizes ~300-
400 µm in diameter) as shown in (c).  In this manner, culture supernatant containing low 
concentrations of mouse IgG may be locally enriched at the chip surface in order to screen 
several antibodies simultaneously.      
 
Figure 54 and Figure 55 indicate the initial spots of goat-anti mouse IgG antibody and the 
subsequent (larger) spots of diluted mouse monoclonal antibody.  Antibodies were diluted 
into cell culture media (DMEM with 10% low IgG FBS) to simulate antibody generated 
via typical cell culture methods.  The antibodies that were spotted onto the chip surface 
represent two different disease targets:  dengue NS1 and Zika envelope protein.   
 
 
(a) 
(c) 
(b) 
Diagram demonstrating localized enrichment of 
antibody diluted into cell culture supernatant 
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Figure 54.  A regularly spaced array of goat anti-mouse IgG antibody was first spotted 
onto a functionalized chip, as shown here.  The ‘wet’ spot image is shown to indicate the 
localized position for each spot. 
 
 
 
 
 
 
 
 
 
 
Figure 55.  After washing and drying the anti-mouse IgG spotted chip, dilutions of antibody 
were subsequently spotted with larger volumes (larger spot diameter) directly on top of the 
anti-mouse IgG spots.  In this manner, we may effectively enrich the antibody present in 
ZV-48 NS1_D2 
1 mg/ml ZV-48 in PBS  
0.1 mg/ml ZV48, diluted 
into culture media 
Goat anti-mouse IgG antibody is first 
spotted onto the IRIS chip 
Dilutions of antibodies into cell culture supernatant are 
subsequently spotted onto the anti-mouse antibody 
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the culture supernatant and attempt to better quantify the reagents.  10-fold dilutions of 
each antibody were spotted in triplicate; the 1 mg/ml ZV-48 antibody was prepped in a 1X 
PBS buffer (stock concentrations) and all subsequent concentrations were diluted into 
media (DMEM with 10% FBS). 
 
Antibodies were prepared in 10-fold dilution steps, ranging from 1 mg/ml → 1 µg/ml.  The 
highest concentration of the stock ZV-48 was 1.0 mg/ml in 1X PBS; therefore, this spotting 
concentration did not include any cell culture media.  After spotting the diluted antibodies, 
the chips were stored overnight at room temperature to reach equilibrium.  The chip was 
subsequently washed, blocked and loaded onto the IRIS stage, as normal, prior to begin-
ning the assay.   
 
After equilibrating the chip, a solution of 10 µg/ml recombinant dengue NS1 (InBios In-
ternational, Inc.) was injected into the microfluidic chamber.  This was followed by buffer 
to record dissociation.  A recombinant Zika envelope protein (also at 10 µg/ml, InBios 
International, Inc.) was subsequently injected to observe binding at the ZV-48 spots, fol-
lowed again by buffer to drive dissociation events. 
 
Figure 56(a) shows the binding events observed at the NS1_D2 antibody spots and Figure 
57(b) shows a still image (from the sequence of ‘difference’ images) representing the 
amount of binding at the spots.  As can be seen, any significant binding occurred at the g-
anti mouse IgG spots, as should be expected.  The NS1_D2 appeared to localize to the anti-
mouse IgG spots during the enrichment process, as desired.  We do immediately note, 
however, that the magnitude of the signal is quite low (see Figure 33 and Figure 37, for 
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instance); even at the 1 mg/ml spotting concentration, absolute signals are ~1/2 those 
obtained when purified antibody is spotted directly onto the chip surface.  This may be due 
to the possibility that only a fraction of the anti-mouse IgG antibodies may be active and/or 
actually target the mouse isotype used in this assay. 
 
Likewise, Figure 56(b) shows the binding events observed at the ZV-48 spots when the 
Zika envelope ligand is injected into the chamber and Figure 57(c) shows a captured image 
representing the binding at each spot.  Again, the ZV-48 antibodies and subsequent reac-
tivity appear to be localized to the anti-mouse IgG spots that sequestered the ZV-48 anti-
body from solution – with the exception of the highest concentration of spotted ZV-48 
antibody.  This reagent stock was at 1 mg/ml in 1X PBS and so no culture media was 
present in these spots; the extraneous active spot that is visible may be due to passive ad-
sorption of the purified antibody to the chip surface.  The magnitude of the ZV-48 signal 
was limited compared to previously obtained signals using purified reagents (see Figure 30 
for reference).   
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Figure 56.  (a) Binding curves obtained for dilutions of NS1 antibody into cell culture 
media (DMEM with 10% low IgG FBS).  (b) Binding curves for dilutions of ZV-48 antibody 
targeting Zika envelope protein.  ZV-48 antibodies were also diluted into cell culture media, 
with the exception of the 1.0 mg/ml ZV-48 (diluted into 1X PBS).       
 
 
 
  
Binding curves for antibodies diluted into cell culture media 
(a) 
(b) 
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Figure 57.  Sample image slices representing the binding events are shown here.  Prior to 
injecting the analyte, no increase in signal (localized mass accumulation) is observed in 
(a).  With the addition of NS1 analyte, the diluted NS1 specific antibodies that have 
associated with the goat-anti mouse IgG spots demonstrated an observable, but modest 
increase in signal at (b).  Upon injecting the Zika envelope protein, the ZV-48 ligands show 
specific binding at (c).  We do note that the 1 mg/ml spot of ZV-48 (diluted into 1X PBS, as 
described in the text) appears to have non-specifically attached to chip with the larger spot 
size apparent.   
 
While it was found certainly possible to screen spots of antibodies at relevant concentra-
tions (~1-10 µg/ml range) diluted into cell culture media, it is also certainly more compli-
cated.  The necessity to pre-spot the chips with g-anti mouse IgG and ensure that the sub-
sequent (larger) spots of diluted antibody are subsequently placed directly on top of the 
capture antibody requires a significant amount of care and additional overnight incuba-
tion steps.  Potential improvements to this approach and methodology will be addressed 
in Chapter 10 Conclusions and further directions. 
 
Example image slices for NS1 and Zika envelope binding events 
(a) (b) (c) 
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Monitoring genetically modified ligands during production and purification 
An additional application of IRIS technology is relevant to the monitoring of modified 
ligands (antibodies) during any genetic manipulation and purification steps.  In one in-
stance, InBios International, Inc. created a humanized chimera antibody of the mouse mon-
oclonal antibody, NS1_D6.  The mouse monoclonal antibody was known to react predom-
inantly with the dengue-4 serotype of the NS1 protein from previous testing (data not 
shown).  It was unknown if making the antibody into a humanized chimera would signifi-
cantly impact the antibody avidity.   
 
To evaluate the activity of the NS1_D6 chimera, a single IRIS chip was spotted with rep-
licates of BSA controls, two other unrelated anti-NS1 antibodies, the control NS1_D6 
mouse monoclonal antibody and the NS1_D6 chimera antibody.  Reagents were spotted in 
replicates of n = 6 using the BioRad BioOdyssey CalligrapherTM (see Figure 58 and Ap-
pendix).  Spot sizes were ~300 µm in diameter.   
 
After incubating the chips at room temperature overnight, the chips were washed and 
blocked following the same standard protocols (see Appendix) and loaded into the IRIS 
system.   After equilibration, the assay was simply performed by (1) Running buffer (1% 
BSA/PBST) only for 10 minutes (2) Injecting a solution of 5 µg/ml dengue-4 NS1 (Native 
Ag. Co.) diluted into buffer (3) Running buffer only for an additional 30 minutes to record 
the dissociation. 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58.  The post-spotting (still ‘wet’) chip is shown here to indicate the spot size, 
locations and morphology.  For perspective on chip dimensions, please refer to Figure 9. 
 
The average of n = 3 spots was used to generate the raw binding curves shown in Figure 
59.   The individual spot replicates (n = 3) were also fit and used to generate the mean and 
standard deviation of the kinetic parameters shown in Table 10.   
 
 
 
‘Wet’ spots of antibody and chimera antibody targeting dengue NS1 
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Figure 59.  The raw binding curves and subsequent fit (using a 1:1 model) are shown in 
(a) and (b), respectively.  
 
  
Recorded binding curves for NS1 mAbs and chimera ligands 
(a) 
(b) 
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REAGENT 𝒌𝒐𝒏  
(𝑴−𝟏𝒔−𝟏)  
𝒌𝒐𝒇𝒇  
(𝒔−𝟏) 
𝑲𝑫 
 (𝑴) 
NS1_D10 (1.30 ± 0.12) 𝑥104 (1.66 ± 0.03) 𝑥10−4 (1.28 ± 0.14) 𝑥10−8 
NS1_D2 MAB (1.22 ± 0.08) 𝑥104 (1.51 ± 0.31) 𝑥10−5 (1.24 ± 0.28) 𝑥10−9 
NS1_D6 CHIMERA (5.05 ± 0.08) 𝑥104 (3.44 ± 0.35) 𝑥10−5 (6.83 ± 0.80) 𝑥10−10 
NS1_D6 MAB (5.80 ± 0.26) 𝑥104 (4.03 ± 2.23) 𝑥10−5 (6.93 ± 3.75) 𝑥10−10 
  
Table 10.  The fit parameters (using a 1:1 binding model) for the NS1 antibodies are shown 
here.  As can be seen, the NS1_D6 mouse monoclonal mAb and the humanized chimera 
antibody (NS1_D6 chimera) demonstrated very similar binding kinetics and 𝐾𝐷 values.  Fit 
parameters represent the mean and standard deviations from fitting results from three 
individual replicate spots. 
 
After reviewing both Table 10 and Figure 59, it may be seen that the humanized chimera 
antibody displays similar binding characteristics to those of the mouse monoclonal and we 
would not expect any deleterious impact on an assay that incorporates the chimera over the 
mouse monoclonal antibody.  The observed mean KD values agreed within a factor of 2% 
while the other two anti-NS1 ligands provided KD values ~50-fold and ~500-fold greater.   
 
Confirming reactivity of subcloned, purified antibodies 
As part of the testing performed for the F1 and LcrV analytes (see Figure 35, Figure 36, 
Table 5 and Table 6) we included three ligands (LcrV_L3_F2, LcrV_L3_5I and 
LcrV_L3_35) that represented efforts for subcloning an antibody cell line.  That is, strict 
clonality of the parent cell line was not guaranteed, and efforts to subclone this ligand were 
undertaken in order to obtain a true monoculture. 
  
Fit parameters for NS1 antibody and chimera 
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Each ligand (LcrV_L3_F2, LcrV_L3_5I and LcrV_L3_35) represented a separate culture, 
separate harvest and separate purification process.  These purified antibodies were spotted 
and the assay run as described earlier (see Figure 35 and surrounding text).  Here, we focus 
specifically on these three reagents and compare the binding characteristics to evaluate if 
we may consider whether or not each clone provides the same binding avidity.  
 
The raw binding curves for each of the three ligands is shown in Figure 60 and the rec-
orded binding characteristics are shown in Table 11.    
  
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60.  The averaged (n = 2 replicates) binding curves for the LcrV_L3 antibody 
subclones are shown in (a).  Langmuir (1:1) binding fits are shown in (b) and bivalent fits 
are shown in (c).     
  
Recorded binding curves for LcrV_L3 subclones 
(a) 
(b) 
(c) 
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  IRIS KINETIC PARAMETERS 1:1 FIT 
REAGENT 𝑘𝑜𝑛  
(𝑀−1𝑠−1)  
𝑘𝑜𝑓𝑓  
(𝑠−1) 
𝐾𝐷 
(𝑀) 
LCRV_L3_F2 1.20 ± 0.09 𝑥105 7.94 ± 2.6  𝑥10−5 6.73 ± 2.63  𝑥10−10 
LCRV_L3_5I 1.22 ± 0.09  𝑥105 6.34 ± 0.3  𝑥10−5 5.49 ± 0.25  𝑥10−10 
LCRV_L3_35 1.60 ± 0.03  𝑥105 6.67 ± 0.17 𝑥10−5 3.91 ± 0.24  𝑥10−10 
Table 11.  The mean and standard deviations (n=2 replicates) for the 1:1 fit parameters for 
the LcrV_L3 ligand subclones are shown here.  There is a slight difference in the mean fit 
value compared to Table 6 as here we estimated fit parameters for each individual curve 
and averaged the fit parameters, whereas in Table 6 the collected binding curve data was 
first averaged prior to fitting for the kinetic parameters.   
 
Evaluating the individual fit values for 𝑘𝑜𝑛, 𝑘𝑜𝑓𝑓 and 𝐾𝐷, we see from Table 11 that the fit 
parameters fell within ~50% of one another.  Considering that each ligand represents a 
different cell culture, purification process and concentration step, the observed binding pa-
rameters appear to be well within acceptable limits and no significant difference between 
the subclones was observed.   
 
Evaluating antigen binding and self-assembly with influenza matrix protein 1 
In addition to monitoring antigen-antibody binding, it may also be possible to monitor self-
assembly (oligomerization) of analyte during a binding assay.  In the following experiment, 
we determine the specificity of binding to influenza matrix protein 1 (M1) variants, observe 
apparent oligomerization of M1 antigen, and also screen for appropriate antibody sandwich 
binding.   
 
Fit parameters (1:1) for LcrV_L3 antibody subclones 
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The influenza matrix protein 1 (M1) is a critical protein for the virus structure and function 
and provides viral stability via the creation of the viral matrix layer (Zhang, et al., 2012) 
(Harris, Forouhar, Qiu, Sha, & Luo, 2001).  The M1 protein may self-assemble (or oli-
gomerize) depending upon buffer conditions.  Complex structures may be formed, includ-
ing stacked dimers, elongated ribbons and helices (Harris, Forouhar, Qiu, Sha, & Luo, 
2001) (Shtykova, et al., 2013).   
 
Antibodies targeting several flu components (hemagglutinin - HA, nucleoprotein - NP and 
matrix protein - M1) were spotted onto a functionalized IRIS chip in triplicate using the 
BioRad BioOdyssey CalligrapherTM.  The antibodies targeting M1 protein were thought to 
be influenza type A specific.  After spotting, the chip was incubated overnight at room 
temperature prior to initiating the assay.  The chip was rinsed, blocked for 45 minutes and 
loaded into the IRIS stage.   
 
All reagents were diluted into 1% BSA/PBST prior to injecting into the IRIS chamber.  
After each binding event, buffer only (1% BSA/PBST) was injected in order to monitor 
dissociation events.  After dissociation, the antibody-antigen pair was eluted by using 0.1 
M glycine, pH 2.5. 
 
Antibodies targeting type A specific M1 were evaluated by first injecting a type B specific 
M1 protein to monitor for potentially cross-reactive M1 reactivity.  Subsequently, three 
different preparations of influenza type A specific M1 proteins were injected into the 
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chamber and the binding and dissociation events were monitored with each sequentially 
injected analyte.  After the injection of the last type A specific M1 protein, the M1 
antibodies themselves (M1_F1 and M1_F2) were sequentially injected into the chamber to 
evaluate complementary binding. 
 
As can be seen in Figure 61(a) and (b), the influenza type A M1 protein binds specifically 
to anti-M1 ligands that are spotted onto the IRIS chip surface.  No significant binding was 
observed with influenza type B M1 protein.  However, we also note that the binding curves 
observed while type A M1 antigen is flowing over the chip appears to be biphasic in nature.  
An initial rapid binding occurs for both anti-M1 antibodies followed by a slower, approx-
imately linear accumulation of analyte at these same spots.  Negative control antibodies 
demonstrate no or minimal non-specific binding to the M1 protein during this binding 
phase.   
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Figure 61.  No specific binding was observed when influenza type B M1 protein was in-
jected into the chamber (a).  Specific, biphasic binding was observed upon the injection 
of type A M1 protein in (b).  A rapid association event is followed by a slower, approxi-
mately linear association event at the corresponding antibodies targeting M1. 
 
 
The biphasic binding behavior observed in Figure 61(b) was observed with each of the 
three influenza type A M1 proteins (for additional reference, see Figure 62).     There appear 
to be two distinct association events that are occurring while the M1 protein is injected into 
the chamber.  This may be indicative that we are observing first the initial binding of M1 
Influenza Matrix protein (M1) binding M1 antibodies 
(a) 
(b) 
M1 (type A) 
Buffer 
M1 (type B) 
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protein to the surface bound anti-M1 antibody at the chip surface, followed by oligomeri-
zation of the M1 protein to itself.  Additional investigations would need to be performed 
to verify that these observations are, in fact, representative of M1 self-assembly near the 
chip surface and not an unidentified measurement artifact.  
 
As previously mentioned, after the last injection of influenza type A M1 protein each of 
the anti-M1 antibodies (M1_F1 and M1_F2) was serially injected (10 µg/ml diluted into 
1% BSA/PBST) into the microfluidic chamber to evaluate the complementary activity of 
each reagent.  As can be seen in Figure 62, the M1_F2 and M1_F1 antibodies complement 
one another (‘sandwich’ each other) but they do not exhibit any significant self-self binding 
characteristics (i.e., they would not be able to ‘sandwich’ themselves).    
 
 
 
 
 
 
 
 
 
Figure 62.  The injection points for influenza type A M1 protein, buffer, M1_F2 antibody 
and M1_F1 antibody are indicated here.  The M1 binding events again demonstrated a 
biphasic behavior (see text).  The (*) indicates when the buffer was switched to ‘re-
circulation’ mode and additional accumulation at the anti-M1 spots begins to occur.  The 
M1 (type A) 
Buffer 
M1_F2 
M1_F1 
Influenza Matrix protein (M1) binding and complemen-
tary antibody binding 
* 
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subsequent injections of M1_F2 and M1_F1 antibodies into the chamber demonstrated 
complementary binding, indicating that these antibodies target distinct epitopes. 
 
However, we also observed that once the IRIS is switched to a ‘re-circulation’ mode (see 
Figure 62), the M1 spots tend to accumulate mass at the specific spots once again; this may 
be indicative of some residual M1 analyte in the tubing that may further bind and associate 
to the anti-M1 spots and the subsequent M1 assembly.   
 
Conclusion: 
The IRIS system has demonstrated significant additional utilities beyond the direct multi-
plexed measurement of kinetic parameters.  Here, we have shown the ability to use the 
IRIS system for screening representative unpurified monoclonal antibody supernatant, ver-
ified the reactivity of genetically modified (human chimera) antibodies, evaluated sub-
cloned antibody lines to ensure consistent activity and monitored the apparent self-assem-
bly of analyte when bound to a spotted ligand.  The IRIS system has proven utility in any 
situation where labeled reagents may not be a viable option (i.e., too expensive, unavailable 
or interferes with the desired assay format) and provides occasionally unexpected observa-
tions.   
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Chapter 10 Conclusions and further directions 
The IRIS system has demonstrated significant utility for the multiplexed determination of 
kinetic information while using minimal sample volume.  Multiple disease systems have 
been evaluated with dozens of ligand-analyte binding pair events recorded simultaneously 
(with unique data sets recorded in 100’s of individual spots, e.g., Figure 43).  Real-time 
feedback provided the opportunity to run potential binding partners to determine appropri-
ate pairs for use in standard immunoassay development (see Figure 43, Figure 44, Figure 
45 and Figure 62 for reference).   
 
Specifically, we have (1) created a simple GUI python program for rapid data analysis 
generated by IRIS kinetic results (2) validated the 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 measurements recorded 
with VHH ligands targeting anthrax analyte to rates determined by SPR (3) compared the 
𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 rates with monoclonal antibodies targeting Zika virus envelope protein to 
BLI (4) demonstrated multiplexed rate determination with dengue antibodies, Y. pestis an-
tibodies, and anthrax ligands (5) verified ‘sandwich’ reactions in IRIS to determine appro-
priate binding pairs in Y. pestis and anthrax immunoassay systems (6) improved previously 
obtained LoD’s for direct analyte detection using IRIS by ~10-fold for two different ana-
lytes (7) demonstrated the ability to screen antibody diluted into tissue culture media (rep-
resenting monoclonal antibody supernatant) (8) verified the activity of genetically modi-
fied humanized chimera antibodies (9) compared the reactivity of antibody subclones and 
(10) demonstrated the evaluation of flu antibody systems targeting matrix protein, M1, 
where initial antibody binding events, possible self-assembly and subsequent antibody 
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sandwiching were observed. 
 
Measurements for 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 were estimated and compared favorably with values ob-
tained using SPR and BLI given the variability of experimental protocols.  The validation 
of estimated kinetic parameters represented two different disease states (anthrax and Zika 
virus), two different ligand types (VHH and monoclonal antibodies) and two different ref-
erence measurement methods (SPR and BLI).  Additionally, simple rank measurements of 
kinetic parameters were readily obtained with the IRIS system as identical (uniform) con-
ditions are applied over the entire chip surface.     
 
Improvements to both the historical IRIS system and the experimental methods for anti-
body-antigen testing have demonstrably improved the limits of detection over previous 
IRIS iterations.   Analytical sensitivity limits approaching single ng/ml levels were ob-
tained for two different analytes (dengue NS1 and Y. pestis F1) representing distinct mo-
lecular weights (~45 kDa and ~17.5 kDa, respectively).  Both real time measurements and 
end point titration estimates for the direct detection of analyte showed significant improve-
ments over previously collected data (see, for reference, Figure 49, Figure 50 and Figure 
52). 
 
Beyond the direct detection of analyte and multiplexed estimation of kinetic parameters, 
the ability to determine the complementary binding activity of potential ligand partners is 
critical for immunoassay development.  The IRIS system has demonstrated the significant 
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flexibility to screen ligands against a wide array of potential binding partners – quickly 
determining appropriate binding pairs from a large variety of options. 
 
The additional utilities of the IRIS system became more apparent with further use.  This 
included the verification of antibody activity after genetic manipulation or during the clon-
ing process, screening antibody from cell culture supernatant and potentially observing 
self-assembly processes during binding events.  Given that the IRIS system monitors the 
real-time direct observation of mass accumulation at geometrically localized spot, the flex-
ibility and utility of this system for reagent analysis, validation and qualification will only 
continue to expand. 
 
The robustness and ease-of-use of the IRIS assay must also be emphasized; unlike SPR 
and BLI systems, there is no typical artificial ‘jump’ in the collected data when buffers are 
injected which subsequently require the data to be re-aligned.  It is also simple to visualize 
the binding at each of the spots while the experiment is running.  Given this immediate 
feedback during each experiment, it is possible to adjust the protocol or the injected ana-
lytes to accommodate the (sometimes unexpected) data that is observed. 
 
Future work may include establishing and optimizing surface chemistry for optimal chip 
stability and functionality, direct comparison of different IRIS chips types (e.g., silicon vs 
nitride IRIS chips), miniaturization of the IRIS setup, automated fluidic control and a com-
pletely integrated software environment (i.e., data collection, reagent control and analysis).  
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Automated fluidic control will be a key future improvement of the IRIS system so that 
experiments may be initiated while permitting the operator to ‘walk away’ while various 
analytes are injected over the chip surface.  Investigations into implementing existing so-
lutions (solenoids, valve selectors, syringe pumps, etc.) are ongoing and will be an imme-
diate improvement to the current IRIS device.  Other future improvements to the IRIS sys-
tem may incorporate information to account for the ‘bulk effect’ of the reagents that are 
injected into the flow cell.  While the data collected with the IRIS system typically does 
not exhibit any significant ‘jump’ in the raw data (when various buffers are injected over 
the surface), it may be possible to further ameliorate shifts in the collected data when ex-
treme changes in refractive index are apparent.  This account of the ‘bulk effect’ may be 
addressed by incorporating a sensor in the integrating sphere to quantify the light intensity 
(and monitor for fluctuations) as the various buffers are injected.   
 
Future optimization for detecting signals in unconcentrated monoclonal antibody superna-
tant may also be pursued.  Injecting the supernatant over the chip surface is trivial to mon-
itor, but multiplexing spots of unconcentrated supernatant onto the IRIS chip surface (given 
the low concentrations of antibody) make this a more difficult platform for high throughput 
screening of culture supernatants.  The ability to spot unmodified antibody supernatants 
directly onto an IRIS chip would immediately open other avenues of investigation using 
this platform. 
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Overall, the IRIS system has demonstrated significant utility in immunoassay design, rea-
gent selection and confirmation of reagent activity.  The ability to rapidly detect paired 
binding events correctly steered ligand selection for further immunoassay development.  In 
addition, the IRIS system has been used to demonstrate serotype specificity, detect com-
petitive epitopes and evaluate complementary antibody activity.  With limits of detection 
nearing or matching current single channel detection methods (e.g., SPR), simplified ligand 
attachment and reduced reagent costs, the IRIS should continue to prove useful in several 
diagnostic and therapeutic applications. 
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Appendix – Selected Methods 
 
Method:  Chip functionalization 
Chips are functionalized using a straightforward epoxysilane (3-(glycidoxipropyl)tri-
methoxysilane) protocol.  Briefly, chips are exposed to (submerged) 1N NaOH for 1 hour 
prior to rinsing in a large volume of deionized water (to remove any remaining salts).  Chips 
are thoroughly dried under an inert gas (e.g., N2) and placed into a clean petri dish.  A fresh 
solution of 3% (v/v) epoxysilane is then immediately prepared, diluted into 100% isopro-
panol.   
 
The 3% epoxysilane solution is quickly poured into the petri dish to submerge the chips.  
The chips are then gently rocked on a rotating rocker plate for 1 hour.  The chips are  rinsed 
in 100% isopropanol for 5 minutes before thoroughly drying under N2.  The chips are sub-
sequently stored under vacuum at room temperature until use (at least overnight to ensure 
the dehydration reaction). 
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Method:  Spotting ligands onto the IRIS chip 
Both ~100 µm capillary and ~300 µm solid type pins have been used successfully, although 
larger spot sizes tend to yield cleaner binding curve data (as the measured surface area is 
increased).  The BioRad BioOdyssey Calligrapher™ has been used for all spotting proce-
dures performed here.  
 
Ligands were typically prepared to concentrations from ~0.2 mg/ml – 1 mg/ml in a PBS 
buffer (to avoid primary amines), containing 1-2% (v/v) glycerol and 1-2% (m/v) D(+) 
trehalose.  The BioRad BioOdyssey Calligrapher™ software was used to determine spot-
ting positions after pulling solutions from a 96-well plate.   
 
After spotting, chips are visually inspected using the IRIS camera to verify spot morphol-
ogy, integrity and to evaluate if any spots may have been missed.   Chips are typically 
incubated overnight at room temperature to allow binding to proceed. 
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Method:  Washing and blocking methods 
After spotting and overnight incubation, chips are washed by holding the chip at an angle 
while simply pouring a 1% BSA/PBST buffer over the chip surface.  The chip is then 
placed into a small petri dish with a 1% BSA/PBST solution on a rocking platform for ~5 
minutes to block.  After blocking, the chip is gently dried under an inert gas (N2). 
 
After washing, blocking and drying, the microfluidic chamber may then be assembled and 
then chip is loaded into the IRIS system. 
 
  
132 
 
 
Method:  Loading the chip into the IRIS 
Immediately after drying the blocked IRIS chip (see above) the microfluidic cartridge is 
assembled and loaded into the IRIS.  This is accomplished by first placing the AR coated 
glass slide (face down) into a custom 3D printed assembly jig (see Figure 5).  A double-
sided pressure sensitive adhesive (PSA) gasket is secured to the AR glass slide.  The dried 
chip is then placed onto the stack and secured via the adhesive to form the microfluidic 
chamber.   
 
After assembly, the protective cover for the AR glass slide is removed.  The cartridge is 
then loaded onto the IRIS stage, ensuring that the TSV holes are in alignment with the 
holes and gasket present on the stage.  A lever is then turned to lower a machined cover 
piece which applies a gentle pressure to the cartridge to ensure a sealed fluidic path. 
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